Gefitinib (ZD1839)

Catalog No.S1025

Molecular Weight(MW): 446.90

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Cited by 95 Publications

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Nature, 2012, 483(7387):100-3

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )
Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )
Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )
Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )
Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )
Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )
PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )
Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

14 Customer Reviews

c, HCC4006 lung cancer cells that have acquired a high-mesenchymal state concomitant with becoming resistant to gefitinib (red curve) exhibit increased sensitivity to GPX4 inhibition.

Nature, 2017, 547(7664):453-457. Gefitinib (ZD1839) purchased from Selleck.

Perturbation of EGFR by its ligand EGF and gefitinib (ZD-1839 Iressat; inhibits EGFR) produces opposite responses in the predicted EGFR target genes SOCS2 and NR2E1.

Mol Syst Biol 2011 7, 486. Gefitinib (ZD1839) purchased from Selleck.
Effects of shRNA-mediated RECK depletion on EGFR signaling in MEFs. (a) Immunoblotting (IB) of the indicated proteins in wild-type MEFs transduced with the indicated shRNAs and cultured for 48 h in the presence of 0.1% dimethyl sulfoxide (DMSO; vehicle) or 1 mM gefitinib (S1025, Selleck Chemicals,Houston, TX, USA). (b) Immunoprecipitation from whole lysates of cells from panel a with an anti-phosphorylated tyrosine (pTyr) antibody. Precipitates from 500 mg protein in whole cell lysates (upper) or 20 mg protein in whole cell lysates (lower) were analyzed by IB with anti-EGFR antibody.

Oncogene 2010 30, 737-750. Gefitinib (ZD1839) purchased from Selleck.

(B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 lM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

Carcinogenesis 2010 31, 1948–1955 . Gefitinib (ZD1839) purchased from Selleck.
LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

Carcinogenesis 2010 31, 1948–1955. Gefitinib (ZD1839) purchased from Selleck.

Suppression of EGFR signaling by Gefitinib is dose dependent and non- toxic at millimolar concentrations.Results from plaque reduction tests of Hep2 cells infected with VACV(12.5pfu/well) treated with a serial dilution of Gefitinib (1000-0.01 m) and analyzed for (A)proliferation as indicator of cytotoxicity,(B) IC50 of plaque size inhibition, (C)dose dependent inhibition of EGFR-ERK1/2signaling and VACV proteins by Western blot analysis (pEGFR detection was obtained from a different experiment with identicals ettings) and (D)dose dependent inhibition of orthopoxvirus genome replication by real-time PCR.Untreated VACV infectedcells and uninfected cells are shown as controls in the right panel.

Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck.
A circular zone of EGFR activated but uninfected cells facilitate virus induced plaque development , efficiently blocked by Gefitinib. (A)Immun of luorescent staining of aplaque reduction tests with Hep2 cells 24,48,72 and 96 h after VACV infection (6.25pfu/chamber). VACV infected cells(green) were visualized by human IgG directed to orthopoxviruses (VIG) detected with a secondary FITC labelled antibody. Uninfected cells with activated EGFR signaling(red) are detected with a secondary Cy3labelled antibody. Positive cells for both , VACV and phosphorylated EGFR are shown in yellow(merge). Cellular nuclei are counterstained with DAPI. (B)Immunofluorescent staining of a plaque reduction test as described for (A) and treated with three different Gefitinib concentrations (1000 nM, 1 nM, and 0.01 nM) . The test was analyzed 96h afterVACV infection.Uninfected cells are shown as controls. Magnification100×.(For interpretation of the references to color in this figure legend , the reader is referred to the web version of the article.)

Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck.

Susceptibility of lung cancer cells to cytolytic activity of NK-92 cells after treatment with EGFR inhibitors. Three lung cancer cells were untreated (open circle) or treated with 10 μM erlotinib or gefitinib (black filled square or black filled triangle) for 24 hours. The lung cancer cells were cocultured with NK-92 cells at indicated effector to target ratio (E:T ratio). To determine the specificity of NKG2D-mediated cytolysis of lung cancer cells, NK-92 cells were preincubated with blocking mAb against NKG2D before the assay (gray filled square and triangle) and correspond-ing isotype mAb (open square and triangle).

J Immunother 2011 34(4), 372-81. Gefitinib (ZD1839) purchased from Selleck.
Inhibition of 5-HT-induced 5-HT3A and 5-HT3AB receptor currents.

Eur J Pharmacol, 2017, 821:21-28. Gefitinib (ZD1839) purchased from Selleck.

The EGF-dependent increased association of PCM1 and AZI1 requires EGFR kinase activity. ZD1839 (Iressa)—EGFR tyrosine kinase inhibitor.

Mol Biosyst 2011 7, 3223-33. Gefitinib (ZD1839) purchased from Selleck.
Reduction of GPER expression in HCC1806 cells after treatment with gefitinib. (A) Concentration dependence. HCC1806 cells were treated with 50-500 nM gefitinib for 48 h. GPER was detected by western blotting. (B) Time dependence. HCC1806 cells were treated with 200 nM gefitinib for 24-96 h. ^ap<0.05 vs. control; ^bp<0.001 vs. control. Mean values and SE of three independent experiments are shown. (C) Representative western blotting of concentration dependence. (D) Representative western blotting of time dependence

Oncol Rep, 2017, 37(2):1212-1218. Gefitinib (ZD1839) purchased from Selleck.

Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

Int J Proteomics 2011 215496. Gefitinib (ZD1839) purchased from Selleck.
Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of Gefitinib for 24 hours.

2010 Dr. Zhang of Tianjin Medical University. Gefitinib (ZD1839) purchased from Selleck.

MTT assay result. 0-500nM Gefitinib treated with H1299, H358, H25 and HCC827 cell lines by 72h, Proliferation rate was tested.

2010 Dr. Vicky Tin from University of Hong Kong. Gefitinib (ZD1839) purchased from Selleck.

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features

A potent EGFR tyrosine kinase inhibitor.

Targets

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

In vitro

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. ^[1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. ^[2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTBwMEW0JO69VQ>?	MYqxOlUyPjR5Mx?=
NIH3T3	MnK2SpVv[3Srb36gRZN{[Xl?	MWGwMlIh\|ryP	NEDaTHEzKGh?	MmPUSG1UVw>?	NELvVWlKdmirYnn0bY9vKG:oIFXHSkB{fGmvdXzheIVlKGi3bXHuJIVz[kJzIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEG0OEDPxE1?	MoLQNVY1QDB{OES=
COS7	M4HpR2Z2dmO2aX;uJGF{e2G7	M2rkSlk3KM7:TR?=			MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGpCUzJiVk[xO2YhdXW2YX70JIV5eHKnc4Pl[C=>	MW[xO\|E4QDd{Mh?=
A549	NHrINYlEgXSxdH;4bYMhSXO\|YYm=		MkTyPVYhcA>?	Ml3YSG1UVw>?	NH\pco1KSzVyPUGzMlU6KM7:TR?=	NIL6SWYyQDNzM{iwOy=>
K562	MkjZR5l1d3SxeHnjJGF{e2G7		MmnGPVYhcA>?	Mnu0SG1UVw>?	MVPJR\|UxRTlwM{[g{txO	MkPhNVg{OTN6MEe=
MDA-MB-231	MkL6R5l1d3SxeHnjJGF{e2G7		NHHmfIU6PiCq	NYH4OHJWTE2VTx?=	MnGyTWM2OD1\|Nj62NUDPxE1?	NHjPeHAyQDNzM{iwOy=>
MOLT4	NYfiPVh7S3m2b4TvfIlkKEG\|c3H5		NH3OdGU6PiCq	MW\EUXNQ	NUPZXJREUUN3ME2xOU4xOiEQvF2=	MVmxPFMyOzhyNx?=
MCF7	NYrmbWpXS3m2b4TvfIlkKEG\|c3H5	M4LSXlUxKM7:TR?=	M2\FfVczKGh?		NFzJOHFKSzVyPUGyMlA2KM7:TR?=	MkPjNVg4PzF6MUm=
BT474	Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml;HO\|IhcA>?		MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKWNEe0JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEWUQnKyJJdqfGhiRVO1NEBw\iByLkOg{txO	NIXwe48yQTB{OESyOC=>
HN5	NWTJZlQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFvYS4I4OiCq		Mk\jRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTkWgZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEWFNUCgc4YhOC5yMTFOwG0>	NHPIWWcyQTB{OESyOC=>
BA/F3	NH7QTWJEgXSxdH;4bYMhSXO\|YYm=		MnnHO\|IhcA>?		NYG0VGVWS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSJI12fGGwdDD3bZRpKEmFNUCgc4YhOC5yMUC4JO69VQ>?	NYfrcnRtOTl{M{myNlk>
NIH3T3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVHITmRQPzJiaB?=		M3G3[mdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJG5KUC9\|VEOgZ4VtdHNiZYjwdoV{e2mwZzDldmIzKGenbnWge4l1cCCLQ{WwJI9nKDBwNUSg{txO	M3jiZVE6PjZ3M{e3
MCF7 MX	MXHGeY5kfGmxbjDBd5NigQ>?		M1rGWlMxKG2rbh?=		Mnr0TY5pcWKrdHnvckBw\iCEQ2LQJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMT6xJO69VQ>?	NUHhT4tMOTl7M{K5OlA>
A431	M17sWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTBcJp{OTBizszN	M17qSVczKGh?		MlrlS2k2OD1yLkWxOEDPxE1?	NHX2[ZUyQTl4OUS2OS=>
A431	MWPLbY5ie2ViQYPzZZk>	MnXlNE4yKM7:TR?=	MW[xJIg>		MVzJcohq[mm2aX;uJI9nKEWJRj3pcoR2[2WmIFXHSnIheGixc4Doc5J6dGG2aX;u	NW\BfZBtOTl7Nkm0OlU>
A431	M2j0e2tqdmG\|ZTDBd5NigQ>?	M2PaXVExOCEQvF2=	M3LBbFExKG2rbh?=		NFm0[Y9Rem:ub37n[YQhcW6qaXLpeI9zgSCjY4Tpeol1gSCxZjDFS2YucW6mdXPl[EBGT0[UIIDoc5NxcG:{eXzheIlwdg>?	MmnhNVk6Pjl2NkW=
Sf9	MW\LbY5ie2ViQYPzZZk>		M1G5ZVExKG2rbh?=	NVvFUYI3TE2VTx?=	M{XRS2lvcGmkaYTpc44hd2ZiRVfGVkBmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\WOncITvdkBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlA{OyEQvF2=	M1jJSVIxODV4NEK1
NCI-H1975	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkf6OUDPxE1?	NIPUbJU4OiCq		NV3wSHk3UUN3ME24MlI3KM7:TR?=	NH[5TI8zODF3MU[3NC=>
NCI-H1975	MmKyT4lv[XOnIFHzd4F6	NX;yfXY1OTBizszN			NVLKNWxFUW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	MlLUNlAyPTF4N{C=
NCI-H1975	NUG2epFDTnWwY4Tpc44hSXO\|YYm=	Ml3aNVAh\|ryP			M2Tr[mlvcGmkaYTpc44hd2ZiRWLCRlIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	MYGyNFE2OTZ5MB?=
NCI-H1975	NV21c4FKTnWwY4Tpc44hSXO\|YYm=	NWLVSnBuPSEQvF2=	M3\ydVQ5KGh?		MnL5TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCjc4Pld5Nm\CCjczDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UuOw>?	Ml\INlAyPTF4N{C=
A375	NYX1WGFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1fzSVQ5KGh?		NX;BToxHUUN3ME2yNE42PSEQvF2=	MWCyNFMxPDV\|Nx?=
SMMC7721	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{nKR\|Q5KGh?		MnHjTWM2OD1\|Mz6xNkDPxE1?	MVKyNFMxPDV\|Nx?=
DU145	NF;IeVBEgXSxdH;4bYMhSXO\|YYm=		NVjPTFBTPSCm	NYLFR2M1TE2VTx?=	MXfJR\|UxRTR{LkG3JO69VQ>?	Mn\SNlA1PjZ3NUW=
MIAPaCa2	NH3VRnNEgXSxdH;4bYMhSXO\|YYm=		NVLx[W4xPSCm	NXLWXIlOTE2VTx?=	NILhT4JKSzVyPUWwMlYzKM7:TR?=	MXiyNFQ3PjV3NR?=
PANC1	MVLDfZRwfG:6aXOgRZN{[Xl?		MYC1JIQ>	M1W1RmROW09?	MnnPTWM2OD12MD60NkDPxE1?	MmTuNlA1PjZ3NUW=
PC9	NIr5[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fBO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSWdHWi2mZX\pZ4lmdnRiaIXtZY4hWEN7IHPlcIx{KHerdHigSWM2OCCxZjCwMlAyPyEQvF2=	M1m0SFIyOjB6OECy
PC9	MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfaW4ZCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBoem:5dHitdoV{cXO2YX70JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiRUe0On9CPzVyL2S3PVBOKG23dHHueEB4cXSqIFXDOVAhd2ZiNzFOwG0>	MW[yNVIxQDhyMh?=
PC3	NFq4cHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlH0NVAh\|ryP	MlyyO\|IhcA>?	MoS0SG1UVw>?	NVTifFdEUUN3ME23MlQh\|ryP	MUiyNVM2OzV2Nh?=
MDA-MB-468	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXmxNFAh\|ryP	NU\rcGRSPDhiaB?=	NWXDWItKTE2VTx?=	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eR?=	M3q5U\|IyPDJ7NkOy
Plasmodium falciparum					Mmf2dWhVWyCycn;mbYxqdmdiZn;yJIlvcGmkaYTvdpMhd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJJBzd2yrZnXyZZRqd25?	NIHaNlkzOThzN{C0OS=>
NCI-H1993	NUP4TWJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2nzRVczKGh?	MUnEUXNQ	NFPGR4RKSzVyPUCuNUDPxE1?	MV2yNVkyPjR\|Mx?=
NCI-H292	MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV23NkBp	MnXHSG1UVw>?	NXSw[41JUUN3ME2wMlAzKM7:TR?=	NGjEOZozOTlzNkSzNy=>
A431	NUP1cpJHU2mwYYPlJGF{e2G7		NV\XV5V2OiCq	NGryW5ZFVVOR	Mnu5TY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBGT0Zvc4TpcZVt[XSnZDDoeY1idiCDNEOxJJdqfGhiSVO1NEBw\iByLkCwNUDPxE1?	NHPSU4QzOjFyMUGzNi=>
MCF7	M4r1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFr2XGoyODEEoN88[{9uVA>?	MWC0PEBp	M{Ph[WROW09?	NGXm[4VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgc5ZmemW6cILld5NqdmdiRVfGVkBo\W6nIIfpeIghUUN3MDDv[kAyOi5yNTFOwG0>	NXXnRVJbOjJzMUmxN\|A>
BT474	MoLuR5l1d3SxeHnjJGF{e2G7	NGj1OWcyOCEQvF2=	MYq0PEBp		MkHDR5l1d3SxeHnjbZR6KGGpYXnud5Qhe2W{dX2td5Rien[nZDDoeY1idiCEVES3OEBk\Wyucx?=	NEG1[YozOjF\|OEOwPC=>
MCF7	NInWVm9EgXSxdH;4bYMhSXO\|YYm=	NYD1VnRqOTBizszN	NIPYToE1QCCq		MXfDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKE2FRkegZ4VtdHNib4\ldk1mgHC{ZYPzbY5oKEW{YlKyJINmdGy\|	NYjlVJVvOjJzM{izNFg>
HCC827	NUTlNm9EU2mwYYPlJGF{e2G7	NV;KTXdTOC5zMkWg{txO	NHPoPVAzPCCq	M1\r[2ROW09?	Mnr5TY5pcWKrdHnvckBw\iCHR1\SJIRmdCCHN{S2MWE4PTBibYX0ZY51KFlzME[4JIF2fG:yaH;zdIhwenmuYYTpc44>	MnTYNlI{Ozl\|NEK=
HCC827	M3\XWGtqdmG\|ZTDBd5NigQ>?	M4\CXlAvOTJ3IN88US=>	NFvOfpIzPCCq	NV30O2NUTE2VTx?=	MlTJTY5pcWKrdHnvckBw\iCHR1\SJIRmdCCHN{S2MWE4PTBibYX0ZY51NW2nZHnheIVlKEW{azDwbI9{eGixconsZZRqd25?	M2riOFIzOzN7M{Sy
HCC827	Mki2T4lv[XOnIFHzd4F6	NHXXZVAxNjF{NTFOwG0>	NWLBVodjOjRiaB?=	NGOwNJVFVVOR	NWjSNWdnUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbDDFO\|Q3NUF5NUCgcZV1[W62LX3l[IlifGWmIFHreEBxcG:\|cHjvdplt[XSrb36=	MkjXNlI{Ozl\|NEK=
A431	NEGyZ3pMcW6jc3WgRZN{[Xl?	M{Pkd\|ExOCEQvF2=	NX3ZOHdrOzBibXnu		MWjJcohq[mm2aX;uJI9nKEWJRmKg[IVzcX[nZDDmdo9uKGi3bXHuJGE1OzFiY3XscEBu\W2kcnHu[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJBwdHlvR3z1MXR6eiCyaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIEGuNFgh\|ryP	NVH4OGMxOjJ4OUi3PFI>
H460	NXnKOJIyS3m2b4TvfIlkKEG\|c3H5		NYDoZW43PzJiaB?=		M{\yUWlEPTB;NT61PUDPxE1?	NYmzeFJ7OjJ5Mke0OFk>
HT-29	NWX1eHlsS3m2b4TvfIlkKEG\|c3H5		NFnTSlc4OiCq		M1;6R2lEPTB;Mz6zOkDPxE1?	M3nC[\|IzPzJ5NES5
SGC7901	NGG4RXdEgXSxdH;4bYMhSXO\|YYm=		Mof6O\|IhcA>?		MVXJR\|UxRTFyLkK2JO69VQ>?	NX7kcnJGOjJ5Mke0OFk>
A498	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7le5JsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFk5KGOnbHzzJIV5eHKnc4PpcochTUeIUjDhcoQhW1KFIIfpeIghUUN3MDDv[kA5NjZizszN	MWOyNlgyQDh2OB?=
Calu3	NUPBeYUyS3m2b4TvfIlkKEG\|c3H5	MYSxNEDPxGdxbVy=	NVXwOYNuPzJiaB?=		MWnJR\|UxRTFwNjFOwG0>	M{HqPFI{OTF4MU[4
FADU	MkDwR5l1d3SxeHnjJGF{e2G7	M{nhWlExKM7:Zz;tUC=>	M1uzZ\|czKGh?		MVLJR\|UxRTBwMEWg{txO	NYL1dHpoOjNzMU[xOlg>
HCC827	NWnTUnBnS3m2b4TvfIlkKEG\|c3H5	M{DYWlExKM7:Zz;tUC=>	Mn7nO\|IhcA>?		MYHJR\|UxRTBwMECxOUDPxE1?	MX2yN\|EyPjF4OB?=
PC9	NFjZXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvufIw5OTBizsznM41N	M4SzRVczKGh?		M{XlNWlEPTB;MD6wNFE1KM7:TR?=	NInSZnAzOzFzNkG2PC=>
Sf9	NULUWIFtU2mwYYPlJGF{e2G7		MWqxJIg>	MX7EUXNQ	NEjTfolKdmirYnn0bY9vKG:oIHj1cYFvKEeVVD30ZYdo\WRiRVfGVkBNQDN2UjDteZRidnRiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjBzNTFOwG0>	MnS2NlM3OTF4OUG=
16HBE14o-	M{LWbWN6fG:2b4jpZ{BCe3OjeR?=	M{jqb\|ExKM7:TR?=	NIjYeoY4OiCq	NHvTdmRFVVOR	MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxOmhDTTF2bz2gZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDFS2ZTKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAyOi55MTFOwG0>	NWH4W41wOjN4Nki0OFE>
NCI-H1975	M2f0XWN6fG:2b4jpZ{BCe3OjeR?=	NHrReIMyOCEQvF2=	NH3VPWI4OiCq	MULEUXNQ	NWXwOoh[S3m2b4TvfIlkcXS7IHHnZYlve3RiZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiNj65NVch\|ryP	MVGyN\|Y3QDR2MR?=
16HBE	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkLXO\|IhcA>?	NXviV5NETE2VTx?=	NH;Xc2VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEG2TGJGKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKge4l1cCCLQ{WwJI9nKDFwNkCxJO69VQ>?	NU\3PYFiOjN5OUKzNVg>
16HBE	Mnz4SpVv[3Srb36gRZN{[Xl?	NGjtZZAyODBizszN	MVSxOVAhdWmw	NGPuOmpFVVOR	MlX6TY5lfWO2aX;uJI9nKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIlvKGi3bXHuJFE3UEKHIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnI>	NU\UVXF2OjN5OUKzNVg>
A549	NEXqTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmrKO\|IhcA>?	M3XrZ2ROW09?	NGPtdpFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJdqdGRidInw[UBGT0[UL3utVoF{KGSncHXu[IVvfCCqdX3hckBCPTR7IHPlcIx{KHerdHigTWM2OCCxZjC0MlYzPiEQvF2=	MXqyN\|c6OjNzOB?=
SH-SY5Y	NG\ZXVdEgXSxdH;4bYMhSXO\|YYm=		MX[3NkBp		NUPJbWRxUUN3ME2xPE4zOSEQvF2=	M3zLXVI{QDdzOUC5
LoVo	M4TTXmtqdmG\|ZTDBd5NigQ>?		M1X6dVIhKGh?	NIHC[IJFVVOR	NV3v[oJoUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wOlIh\|ryP	Mmj3NlM6OzB7OUS=
PC9	MXrLbY5ie2ViQYPzZZk>		MX2yJIg>	MlnMSG1UVw>?	NXLB[45wUW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wNFg4KM7:TR?=	MV6yN\|k{ODl7NB?=
HCC827	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1rxdVczKGh?		NWn1TVdXUUN3ME2wMlAyOiEQvF2=	M376OFI{QTd\|MU[4
A549	MoPzT4lv[XOnIFHzd4F6	NYPWeo1qOSEQvF2=	MnGxNUBp	M1;te2ROW09?	NGXqToZKdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzl7IN88US=>	NHO2O4gzOzl6OEO1OC=>
A549	MVPGeY5kfGmxbjDBd5NigQ>?	MkHGNUDPxE1?	MlfYNUBp	MkW4SG1UVw>?	NWe1U5dTS2WubIXsZZIhfXC2YXvl	Mmi3NlM6QDh\|NUS=
HCC827	M4nGTmtqdmG\|ZTDBd5NigQ>?	NH3zSVUxNjVizszN	MXSyJIg>	M13TRmROW09?	M{\rNmlvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36gbY4h\2WoaYTpcoljNXKnc3nzeIFvfCCqdX3hckBJS0N6MkegZ4VtdHN?	NVXNcVR{OjN7OUOzNlg>
HCC827	NETTRWZHfW6ldHnvckBCe3OjeR?=	MlHQNE42KM7:TR?=	NFHTO4gzKGh?	MmPPSG1UVw>?	NUfUWYhMUW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hcW5iZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCKQ1O4Nlch[2WubIO=	M3mwelI{QTl\|M{K4
HCC827	NX;xZ3JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInIN2QyOCEQvF2=	MUG3NkBp	MX;EUXNQ	NV3ndYw2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBo\W[rdHnubYIue2Wwc3n0bZZmKGi3bXHuJGhESzh{NzDj[YxteyCqYYLic5JqdmdiRVfGVkBGPzR4IITvJGE4PTBiZHXs[ZRqd25id3n0bEBKSzVyIH;mJFAvODB3OEGg{txO	NVPnVnVCOjRyNUO2O\|Q>
A431	NUHmOopqU2mwYYPlJGF{e2G7	MmC4NVAxKM7:TR?=	M13MTlMxKG2rbh?=		NGDiU5ZKdmirYnn0bY9vKG:oIFXHSnIhcW5ic3jl[EBu\W2kcnHu[UB3\XOrY3zld{B4cXSqIFnDOVAhd2ZiMT6xJO69VQ>?	MnT0NlQxQTR2M{K=
BCRP-MDCK2	MmD0SpVv[3Srb36gRZN{[Xl?	MkP4NU45KM7:TR?=	M1nzRlczKGh?	NIexRW1FVVOR	NGfuW\|BKdmO{ZXHz[UBw\iCybHHzcYEhdWWvYoLhcoUh\XiycnXzd4lwdiCxZjDCR3JRKGW6cILld5NqdmdicnXwc5J1\XJiZ3Xu[UBITlB?	MnLMNlQyQDR{MUO=
BCRP-MDCK2	M2r0WGZ2dmO2aX;uJGF{e2G7	Mn;rNU45KM7:TR?=	NGrQem84OiCq	MXrEUXNQ	NUfmO21SWmWmdXP0bY9vKG:oIIDsZZNu[SCvZX3idoFv\SCneIDy[ZN{cW:wIH;mJGJEWlBiZYjwdoV{e2mwZzDy[ZBwenSncjDn[Y5mKEeIUB?=	M1fndFI1OTh2MkGz
MDCK	MlnxR5l1d3SxeHnjJGF{e2G7		MY[3NkBp	NELLempFVVOR	NVLwcGlWT0l3ME2xMlQ2KM7:TR?=	MnS1NlQyQDR{MUO=
MDCK2	M{LaPWZ2dmO2aX;uJGF{e2G7	NU\reIFWOS56IN88US=>	MUG3NkBp	MVzEUXNQ	NGnKXmZKdmirYnn0bY9vKG:oIHj1cYFvKEKFUmCg[ZhxemW\|c3XkJIF{e2W\|c3XkJIF{KEixZXPod5QhOzN\|NEKgZYNkfW23bHH0bY9vKHerdHigTWM2OCCxZjCzMlE6KM7:TR?=	M4\RUFI1OTh2MkGz
A431	MXrDfZRwfG:6aXOgRZN{[Xl?		NYn5eWhCPzJiaB?=	NUTjOFhtTE2VTx?=	MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOC53NTFOwG0>	M{PSNVI1PDFzMUKz
Calu3	MWXDfZRwfG:6aXOgRZN{[Xl?		MYi3NkBp	MX3EUXNQ	M3\2UWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNidHV\|IHPlcIx{KGW6cILld5NqdmdiSFXSNkB4cXSqIFnDOVAhd2ZiMD65PUDPxE1?	M1uyd\|I1PDFzMUKz
KB	NGDQOpJMcW6jc3WgRZN{[Xl?	M{nKfVExKM7:TR?=	MVexJIg>	M2rn[GROW09?	M{fkeWlvcGmkaYTpc44hd2ZiRVfGMZN1cW23bHH0[YQh[XW2b4Doc5NxcG:{eXzheIlwdiCxZjDFS2ZTKHerdHigTWM2OCCxZjCwMlAzPSEQvF2=	MXyyOFQyOTF{Mx?=
BEAS2B	M2XoSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWm1NEDPxE1?	NV[wfZQzPzJiaB?=	Ml73SG1UVw>?	MVvJR\|UxRTF\|Lkm0JO69VQ>?	NIDHbIwzPDZyN{W5NS=>
NCI-H1975	Ml3pSpVv[3Srb36gRZN{[Xl?	NWjGZnJwOTByIN88US=>	M{j5[FE2OCCvaX6=	M1\4WmROW09?	MWLJcoR2[3Srb36gc4YhVk9icILv[JVkfGmxbjDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51	MmP5NlQ3ODd3OUG=
Hela	M3TxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{n0NVI1KGh?	M2rBRWROW09?	M1HZd2lEPTB;Mj62O{DPxE1?	M1jPS\|I1PzNzMkix
HepG2	M4\aXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXjFbIwxOjRiaB?=	M33HfmROW09?	NYWxT3NMUUN3ME22MlQzKM7:TR?=	NFLhdIYzPDd\|MUK4NS=>
Sf9	M17ES2tqdmG\|ZTDBd5NigQ>?		NVnQdm9zOTBibXnu	M4j4U2ROW09?	NY\lfnR{UW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKHKnY3;tZolv[W62IHjpd{11[WepZXSgSWdHWiBqYX3pco8h[WOrZDC2OFUuOTF6Njmg[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>?	MXuyOFc{OTJ6MR?=
SW620	M3HE[mN6fG:2b4jpZ{BCe3OjeR?=		NIDYVVc1QCCq	NVnCe5NiTE2VTx?=	NEK2eXlKSzVyPUK4MlIh\|ryP	NGe1O44zPDlyMEW5OC=>
HCC827	MVfGeY5kfGmxbjDBd5NigQ>?	MWOwMlUh\|ryP	NE\RNGkzKGh?	MUfEUXNQ	NG\VRZBld2W\|IH7veEBqdmirYnn0JIMuVWW2IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQVvUJJBpd3OyaH;yfYxifGmxbh?=	M2fGSFI{QTl\|M{K4
HCC827	NF3RXWRHfW6ldHnvckBCe3OjeR?=	NGC2So0xNjVizszN	MWWyJIg>	MljHSG1UVw>?	MVfkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDR2L{SyJJBpd3OyaH;yfYxifGmxbh?=	MXuyN\|k6OzN{OB?=
HCC827	NGDGR3REgXSxdH;4bYMhSXO\|YYm=	M2fZSVAvPSEQvF2=	M{e4W\|czKGh?	M1WwemROW09?	NFjudHZp[XNibn:gZ5l1d3SxeHnjbZR6	MXSyN\|k6OzN{OB?=
NCI-H1975	NHnPV3pHfW6ldHnvckBCe3OjeR?=	MUOxNEDPxE1?	MUG4JIg>	MXvEUXNQ	MWPkc4V{KG6xdDDpcohq[mm2aTDFS2ZTKGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9v	MmLBNlMyOTZzNki=
A431	M3fi[mtqdmG\|ZTDBd5NigQ>?	MkfNNUDPxE1?	NGH4clcyKGh?	MmX0SG1UVw>?	MljIbIF{KG6xIHnydoV3\XK\|aXLs[UBqdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	NWDEZ5dQOjR7MEC1PVQ>
LNCaP	MYTGeY5kfGmxbjDBd5NigQ>?	NFv1SFEyOCEQvF2=	M2\Dd\|JpKG:{IESgbC=>	M2TKbGROW09?	MlHq[I9meyCwb4SgbY5pcWKrdDDheZRweGixc4Doc5J6dGG2aX;uJI9nKGmvbYXuc5B2emmoaXXkJIZt[WdvdHHn[4VlKEKveDDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{OlCfQWTQ	NELRfoQyQDZ4N{OxNi=>
H1975	MlTFT4lv[XOnIFHzd4F6	Ml;HNUDPxE1?	NWfY[3VzOjRiaB?=	NIjPUY5FVVOR	M4K0VYRw\XNibn;0JIlvcGmkaYSgSWdHWiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51	NUXwblBTOjR4MEe1PVE>
H1975	NGHpOmZHfW6ldHnvckBCe3OjeR?=	NWTxW2pROSEQvF2=	M2HVcFI1KGh?	NGPLXmpFVVOR	MV3kc4V{KG6xdDDpcohq[mm2IFXST{BxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0>	NYPudJFROjR4MEe1PVE>
HCC827	MWTLbY5ie2ViQYPzZZk>	NU\YRXFpOC5zMTFOwG0>	MlXmNUBp	NVXFdohNTE2VTx?=	M2TmZYhieyCwbzDpdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG\|c3Xzd4VlKGG\|IILlZ493\XK7IH;mJGVITlJiYYX0c5Bpd3OyaH;yfYxifGmxbh?=	MVuyOFEzPDh7OB?=
H1975	MX\LbY5ie2ViQYPzZZk>	NUXmSoZsOC5\|MzFOwG0>	MUeyJIg>	NYC5ZlM3TE2VTx?=	NX21SpJq\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEGNVDDwbI9{eGixconsZZRqd25?	M4Lxe\|I1OTJ2OEm4
H1975	M2njSWtqdmG\|ZTDBd5NigQ>?	NITDVJIxNjN\|IN88US=>	MnXINkBp	MX;EUXNQ	Ml;S[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGVTUyCyaH;zdIhwenmuYYTpc44>	MV[yOFEzPDh7OB?=
H1975	NHvxRpNMcW6jc3WgRZN{[Xl?	Mm\hNE4{OyEQvF2=	MmC5NkBp	MoLuSG1UVw>?	MnS3[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQheGixc4Doc5J6dGG2aX;u	MkjRNlQyOjR6OUi=
H1975	NVfqZmFCU2mwYYPlJGF{e2G7	NXLoeVU6OC5zMkWg{txO	MYeyOEBp	MlLwSG1UVw>?	MVPkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51KFlzME[4JIF2fG:yaH;zdIhwenmuYYTpc44>	NVvNS4FqOjJ\|M{mzOFI>
H1975	NGPtSZdMcW6jc3WgRZN{[Xl?	MVGwMlUh\|ryP	MnrVNlQhcA>?	NInZfoFFVVOR	M3G2eYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRvbXXkbYF1\WRiRYLrJJBpd3OyaH;yfYxifGmxbh?=	NVzLOlR1OjJ\|M{mzOFI>
H1975	MWHLbY5ie2ViQYPzZZk>	NX3FZY9POC53IN88US=>	MmnqNlQhcA>?	NHj1RpVFVVOR	MnXR[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfC2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w	MUiyNlM{QTN2Mh?=
MIAPaCa2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXSyMlUh\|ryP	MojVO\|IhcA>?	MXPEUXNQ	M4Hm[ohieyCwbzDndo94fGhiaX7obYJqfGmxbh?=	M4jsNVIxPDZ4NUW1
MIAPaCa2	NG\KXFBEgXSxdH;4bYMhSXO\|YYm=	NYqz[IhjOSEQvF2=	M3rKdVExKGR?	M{X4dGROW09?	M32yd4hieyCwbzDjfZRwfG:6aXPpeJkh[XO\|ZYPz[YQh[XNic4XwdJJme3Orb36gc4Yh[2:ub375JIZwem2jdHnvci=>	NH[2THozODR4NkW1OS=>
MIAPaCa2	NELpcI5CeG:ydH;zbZMhSXO\|YYm=	MU[xNEDPxE1?	NH\xZVYzPGhib4KgOFghcA>?	MVPEUXNQ	MoWx[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	MXKyNFQ3PjV3NR?=
MIAPaCa2	MlS0RZBweHSxc3nzJGF{e2G7	MnizNlAh\|ryP	NHXVRZEzPCCq	NWHqNXR5TE2VTx?=	Mon4[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bk[XOyYYPlJFMh[WO2aY\heIlwdg>?	M3K4VVIxPDZ4NUW1
EoL-1	M37GPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXWfphxUUN3ME21MlE4KG6P	M1vRR3NCVkeHUh?=
NCI-H720	NE\se\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTJ4LkmyJI5O	NETXVoRUSU6JRWK=
NCI-SNU-5	NXiwOZZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJ6LkG5JI5O	MWTTRW5ITVJ?
EW-3	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\6VmlEPTB;NE[uNFQhdk1?	MYLTRW5ITVJ?
HCC2218	NHnNVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlf6TWM2OD13MD61PUBvVQ>?	Ml;MV2FPT0WU
HuO-3N1	M{HkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzBTWM2OD13Nj6wPUBvVQ>?	NXW5WlNzW0GQR1XS
DB	M2j3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PWbGlEPTB;NkCuPVYhdk1?	MUDTRW5ITVJ?
HSC-4	Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUG3R\|ZGUUN3ME22NU42OyCwTR?=	M4HvfXNCVkeHUh?=
DOK	NEn0[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jTc2lEPTB;OUOuOlIhdk1?	MWLTRW5ITVJ?
H9	NVyxOnB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTF\|Nz6yJI5O	NYLvRXN4W0GQR1XS
NCI-H292	NGfMU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDoclFEUUN3ME2xOlIvPjZibl2=	M4DybHNCVkeHUh?=
HSC-2	Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLrTWM2OD1zNkWuOVchdk1?	NXy1RoZFW0GQR1XS
LU-65	MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4e3e2lEPTB;MU[2MlYyKG6P	MWXTRW5ITVJ?
BV-173	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\lTWM2OD1zOE[uOVUhdk1?	M3PRdXNCVkeHUh?=
LB2241-RCC	M3nUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;VTWM2OD1zOUSuPVMhdk1?	MXvTRW5ITVJ?
KG-1	M2HX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1SwdGlEPTB;MkC0MlM1KG6P	MmnvV2FPT0WU
CHL-1	Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTJyOD61NUBvVQ>?	NUDkOZhUW0GQR1XS
KYSE-140	NHLjZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\oSItzUUN3ME2yNFkvQTZibl2=	NEDjOmtUSU6JRWK=
DU-145	M3y4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PyT2lEPTB;MkG5MlA1KG6P	M2HDbHNCVkeHUh?=
EW-13	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\nTWM2OD1{MkWuNUBvVQ>?	MmTtV2FPT0WU
KYSE-450	NXn1XpB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEGwVGJKSzVyPUK0O{46OiCwTR?=	MVnTRW5ITVJ?
CAL-72	M1rwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorpTWM2OD1{NkiuO\|Mhdk1?	NYXlbJdCW0GQR1XS
MEG-01	NIPP[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnDTWM2OD1{N{[uO\|Yhdk1?	M3P5c3NCVkeHUh?=
HCE-T	MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1O2VWlEPTB;Mke5Mlc6KG6P	M2HLd3NCVkeHUh?=
NCI-SNU-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTJ6Mz6zNkBvVQ>?	NXrmVZdGW0GQR1XS
CAL-27	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnvTWM2OD1{OEmuNFghdk1?	MVLTRW5ITVJ?
BALL-1	NVLyN5AzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfDfYlSUUN3ME2yPVcvPDJibl2=	M3nVcHNCVkeHUh?=
SBC-1	NXGxVYpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmS2TWM2OD1\|MEeuO\|khdk1?	MWPTRW5ITVJ?
CAL-54	MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDUNmVKSzVyPUOxNU4zOyCwTR?=	M{LQcnNCVkeHUh?=
TI-73	MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTNzMj63OUBvVQ>?	MkTJV2FPT0WU
P12-ICHIKAWA	Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfFTWM2OD1\|MkiuNFYhdk1?	MY\TRW5ITVJ?
ACHN	MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPkR21SUUN3ME2zN\|EvPCCwTR?=	MWHTRW5ITVJ?
PC-14	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\vR291UUN3ME2zN\|MvPDFibl2=	Mn[xV2FPT0WU
HCC1806	Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTN\|Nz61NUBvVQ>?	M1jLNnNCVkeHUh?=
SK-MEL-24	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTN\|Nz64O{BvVQ>?	NFPP[oNUSU6JRWK=
A4-Fuk	NWe3WGtIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XyPWlEPTB;M{WwMlAzKG6P	Mof4V2FPT0WU
ECC10	NEH1cmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTN3Mj65OkBvVQ>?	MXzTRW5ITVJ?
KASUMI-1	NFfpTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXBcGZKSzVyPUO2Ok44OyCwTR?=	NFG2XVBUSU6JRWK=
CAL-33	NF:wc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13RcmlEPTB;M{ewMlkhdk1?	NH22NW1USU6JRWK=
MDA-MB-175-VII	NIS1bXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTN5OD64PEBvVQ>?	NVXqZWl3W0GQR1XS
NUGC-3	M{nMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\iO\|FkUUN3ME20NFEvQDFibl2=	M4CybHNCVkeHUh?=
KY821	MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rTfWlEPTB;NEC4MlU4KG6P	MlHRV2FPT0WU
CTB-1	NWC2Nmc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlroTWM2OD12MkSuOEBvVQ>?	MlrhV2FPT0WU
DoTc2-4510	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXKTWM2OD12NEKuNVIhdk1?	NEXjVlJUSU6JRWK=
EFO-27	NXLwWIwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fQNGlEPTB;NEW0Mlc1KG6P	Ml\OV2FPT0WU
BPH-1	MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjTTWM2OD12OUGuNVYhdk1?	Mm\iV2FPT0WU
KYSE-270	NXe2SZdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrWSlVKSzVyPUS5PE43PSCwTR?=	M2DCVnNCVkeHUh?=
HO-1-N-1	NXjWTmFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHn5RopKSzVyPUWwPU4zPSCwTR?=	NF30W2tUSU6JRWK=
SK-MEL-1	M132UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTVzMD65PUBvVQ>?	NETSSGFUSU6JRWK=
MOLT-13	M3rIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3K4c2lEPTB;NUG0MlgzKG6P	NGGwd\|RUSU6JRWK=
TK10	NF\oXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7lUGJyUUN3ME21NVUvOTFibl2=	M4i5U3NCVkeHUh?=
HN	M4PaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2C0VWlEPTB;NUG3MlM5KG6P	NHv3R4lUSU6JRWK=
SCC-15	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlmwTWM2OD13MkWuOlghdk1?	NVrCTY1ZW0GQR1XS
NCI-H358	NHjaXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zBe2lEPTB;NUK3MlY3KG6P	M3jTOXNCVkeHUh?=
KYSE-180	NFexUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIP4TIZKSzVyPUWzNE43OiCwTR?=	NULrSYlyW0GQR1XS
NCI-H82	NXS2O3lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTV2MD61JI5O	MljOV2FPT0WU
NB7	NUTZO4FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zYemlEPTB;NUS2MlMzKG6P	NXjEO3VHW0GQR1XS
DSH1	M{nieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;qcWlEPTB;NU[2Mlg5KG6P	MXHTRW5ITVJ?
RS4-11	M3rYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XacWlEPTB;NU[4MlU6KG6P	NXyzeWVzW0GQR1XS
CAN	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTV6MD63OkBvVQ>?	MlvlV2FPT0WU
Ca9-22	MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\NTWM2OD13OEiuOlQhdk1?	MVzTRW5ITVJ?
CAL-39	M161O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13DPWlEPTB;NUm2MlMhdk1?	MmizV2FPT0WU
NCI-H1623	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;jToZPUUN3ME21PVkvOzZibl2=	NYOwT2VLW0GQR1XS
FADU	M{DtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDGTWM2OD14MESuOlkhdk1?	MlfXV2FPT0WU
NB69	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDVNXN4UUN3ME22NVQvOzVibl2=	NHqzbZBUSU6JRWK=
Ramos-2G6-4C10	M17yV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHIZ3ZzUUN3ME22NlEvPDZibl2=	NH3mUHBUSU6JRWK=
LB1047-RCC	MmDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrJWoNJUUN3ME22NlUvOjlibl2=	NG\BWVBUSU6JRWK=
MV-4-11	NYXpTWlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHzTWM2OD14MkeuO{BvVQ>?	NITxR4JUSU6JRWK=
DBTRG-05MG	MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlH5TWM2OD14M{KuNlghdk1?	NWPJd5Y6W0GQR1XS
ME-180	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHUTWM2OD14M{KuPUBvVQ>?	NVj1T3Z6W0GQR1XS
NBsusSR	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\STVM3UUN3ME22OFYvPTJibl2=	NF3HbmxUSU6JRWK=
COR-L105	NXHneJl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfIN3NlUUN3ME22OlIvPTNibl2=	NXvZd5prW0GQR1XS
ETK-1	M4jRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnmTWM2OD14NkKuOVkhdk1?	MWDTRW5ITVJ?
L-363	NWr2[VNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTZ5MT65OEBvVQ>?	NV3PdFROW0GQR1XS
LU-134-A	M2Dz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1uyfGlEPTB;N{G5MlA6KG6P	MV;TRW5ITVJ?
NCI-H1770	M4SyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17CW2lEPTB;N{KyMlQhdk1?	NF3vcXhUSU6JRWK=
HAL-01	NGj4VVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDycnJKSzVyPUezOE44OSCwTR?=	MmTwV2FPT0WU
COLO-684	M33K[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vwZ2lEPTB;N{WzMlAyKG6P	NFH0SmRUSU6JRWK=
TE-6	Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfYRYxsUUN3ME23OlQvOzFibl2=	MUTTRW5ITVJ?
A431	Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTp[oRzUUN3ME23PFAvODRibl2=	MX;TRW5ITVJ?
LU-135	MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGq1fYxKSzVyPUe4N{4xOyCwTR?=	NYnSNpZ3W0GQR1XS
EC-GI-10	Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPyTWM2OD15OEiuOVIhdk1?	MnfDV2FPT0WU
TE-12	NXfGb4FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zIRWlEPTB;OEKxMlEyKG6P	MoHMV2FPT0WU
LoVo	M1HiT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7CXnA3UUN3ME24OVkvODZibl2=	NGLEOYVUSU6JRWK=
23132-87	NVHtOpU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHz4UWRKSzVyPUi2OE4zQCCwTR?=	M3noV3NCVkeHUh?=
AU565	M3\MUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoiwTWM2OD16NkmuOkBvVQ>?	NG\ONFJUSU6JRWK=
DEL	NXHZb4N5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmf0TWM2OD16N{euOlUhdk1?	MnrGV2FPT0WU
COR-L88	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrJTpV7UUN3ME24PFIvOjZibl2=	MYHTRW5ITVJ?
NCI-H2126	NWXvRoZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjVO2ZKSzVyPUi4Nk45OyCwTR?=	MonrV2FPT0WU
CAPAN-1	MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4i4U2lEPTB;OEizMlI6KG6P	NYLZNolxW0GQR1XS
BT-474	M3zLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4Hq[2lEPTB;OUO4MlE1KG6P	NICxXlBUSU6JRWK=
BHY	NH72b3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPTTWM2OD17N{WuOFghdk1?	NVy3[mxYW0GQR1XS
HT-3	NUDheYZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\jTWlEPTB;OUiyMlQyKG6P	MmLjV2FPT0WU
SK-NEP-1	NF\HbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3sTWM2OD17OEmuOFQhdk1?	NW\lfZNFW0GQR1XS
MS-1	NFv3b\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDLVGxKSzVyPUm5OE43QSCwTR?=	NGTuVnJUSU6JRWK=
DOHH-2	NUTWelhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzUOY9mUUN3ME2xMlAxODJzIN88US=>	MYPTRW5ITVJ?
NCI-H1304	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHB[otKSzVyPUGuNFE3PDNizszN	MXTTRW5ITVJ?
EM-2	Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvEZ\|FKSzVyPUGuNFMxOTZizszN	NFrl[nNUSU6JRWK=
MHH-PREB-1	MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvmRnZKSzVyPUGuNFg1PTFizszN	M3u4WHNCVkeHUh?=
KU-19-19	NYTBeVNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPlb\|FKSzVyPUGuNFg2PDFizszN	MlnuV2FPT0WU
NCI-H1648	NHz4NWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTFwMUC2NVYh\|ryP	NFjh[GxUSU6JRWK=
MKN1	M1m4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1L6NmlEPTB;MT6yNVk5PyEQvF2=	M3;nZnNCVkeHUh?=
SNU-449	NX[yb2MzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTFwMkKyNFgh\|ryP	MYHTRW5ITVJ?
OAW-42	NF;KNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVL2[2xHUUN3ME2xMlI4QDJ3IN88US=>	MYDTRW5ITVJ?
769-P	NYPjXJdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1L2TGlEPTB;MT6yO\|kyQCEQvF2=	MWrTRW5ITVJ?
SW1088	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nJR2lEPTB;MT6yPVYxPyEQvF2=	NU\WR5NbW0GQR1XS
GCIY	M4\5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHiOWc3UUN3ME2xMlMxOTN{IN88US=>	NW\veXhPW0GQR1XS
CTV-1	M1u3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{T5XGlEPTB;MT6zNFgh\|ryP	NVjnbnZrW0GQR1XS
NCI-H1092	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTFwM{C4OUDPxE1?	NU\sRmtXW0GQR1XS
NKM-1	NVzzZlZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFwM{K1PVch\|ryP	MVjTRW5ITVJ?
NCI-H1650	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;VRmlEPTB;MT6zN\|Q5OiEQvF2=	NVX0VVJNW0GQR1XS
SW954	M3v0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4iySWlEPTB;MT6zOFA1QCEQvF2=	Mn3QV2FPT0WU
SW48	NF3nSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvvUo0yUUN3ME2xMlM3PjF6IN88US=>	MlPVV2FPT0WU
SK-N-DZ	NX\JRVVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLtNG9NUUN3ME2xMlM3QTR5IN88US=>	M4TRXHNCVkeHUh?=
KMOE-2	MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DvcGlEPTB;MT6zPVgyPSEQvF2=	NXf4b3FlW0GQR1XS
NB5	M2nwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLpb2ZbUUN3ME2xMlQxQDl2IN88US=>	MmDHV2FPT0WU
CCRF-CEM	NFXR[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWT2OHVRUUN3ME2xMlQyOTFizszN	M33U[nNCVkeHUh?=
RH-1	NV;wc4w{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYf3PGpRUUN3ME2xMlQyOTN4IN88US=>	MmDiV2FPT0WU
NCI-H526	NWTZc4dsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPZfFJsUUN3ME2xMlQ{QDJ4IN88US=>	M{HwV3NCVkeHUh?=
697	NGDmNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGG5S5JKSzVyPUGuOFQyODRizszN	MkPJV2FPT0WU
J82	NEGxWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkW3TWM2OD1zLkS1O\|Y3KM7:TR?=	NIrGXVVUSU6JRWK=
BE-13	MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvvTWM2OD1zLkWwOlcyKM7:TR?=	NULZSJdTW0GQR1XS
SAS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUG2[YFXUUN3ME2xMlUyPjJ{IN88US=>	M1nFN3NCVkeHUh?=
SCC-25	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTFwNUKzNlIh\|ryP	MYLTRW5ITVJ?
LAMA-84	MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTFwNUO4NVUh\|ryP	M{jwcHNCVkeHUh?=
HSC-3	NGTBN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVywT4Q2UUN3ME2xMlU1OzhizszN	MlnnV2FPT0WU
BT-549	NGTRflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTFwNUi3OFch\|ryP	MnTCV2FPT0WU
ML-2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M373NWlEPTB;MT62OFAzQSEQvF2=	NF;ZWGxUSU6JRWK=
BB30-HNC	NYHEO2hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTBR5JTUUN3ME2xMlY5QTd{IN88US=>	NWWwWoRTW0GQR1XS
PANC-03-27	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTtXGRUUUN3ME2xMlcxOTN7IN88US=>	MlvRV2FPT0WU
COLO-678	M1n0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkH1TWM2OD1zLkezOFQ1KM7:TR?=	MYnTRW5ITVJ?
NCI-H1666	NEXBTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnn4TWM2OD1zLke0O\|A1KM7:TR?=	M3PuSHNCVkeHUh?=
NCI-H209	NXHDVJlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUO2WItNUUN3ME2xMlc4OjZ7IN88US=>	NIHLdnZUSU6JRWK=
EPLC-272H	M4TjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHQTWM2OD1zLki1OVQ6KM7:TR?=	MVPTRW5ITVJ?
OMC-1	MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjkXlhKSzVyPUGuPVk5QDhizszN	NIHuO2dUSU6JRWK=
HCC70	NXrjUW94T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTJwMEC4NVUh\|ryP	M3PtNXNCVkeHUh?=
CAL-12T	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWH4SphTUUN3ME2yMlAyQDZzIN88US=>	MUHTRW5ITVJ?
TGBC24TKB	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4Pj[GlEPTB;Mj6wNlk3OSEQvF2=	NVHzVo9rW0GQR1XS
EKVX	NHLifHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDDR\|YyUUN3ME2yMlA1QTN7IN88US=>	MX\TRW5ITVJ?
SW1116	MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHyVXJ4UUN3ME2yMlA3ODB7IN88US=>	M3P2b3NCVkeHUh?=
NCI-H2009	NWn6WIVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPYTWM2OD1{LkC2NlE1KM7:TR?=	M{\GenNCVkeHUh?=
RPMI-8866	NXLweIROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\1T5hKSzVyPUKuNFg1QDFizszN	NU\iXFVbW0GQR1XS
KARPAS-45	MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTJwMUK0O\|kh\|ryP	MlrrV2FPT0WU
RXF393	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWmwOWxNUUN3ME2yMlE{ODN4IN88US=>	MVjTRW5ITVJ?
786-0	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPPNmdKSzVyPUKuNVg1ODZizszN	M1PWUHNCVkeHUh?=
SCC-4	NFvzbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HrN2lEPTB;Mj6yNVc4PiEQvF2=	NHjaXlFUSU6JRWK=
BT-20	NYf1NFdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4G4fmlEPTB;Mj6yOlc1PCEQvF2=	M3rBVnNCVkeHUh?=
A498	M3;IPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHf0bGVKSzVyPUKuNlk1OTVizszN	NWr3VWplW0GQR1XS
IGROV-1	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3KyWWlEPTB;Mj6zNVI{PyEQvF2=	Mm\EV2FPT0WU
JVM-3	NIWwW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTETWM2OD1{LkO0OlQ{KM7:TR?=	MlLJV2FPT0WU
NCI-H2170	NWqxdWJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\3cWlEPTB;Mj6zOFc5OyEQvF2=	MYHTRW5ITVJ?
EW-18	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\DfWpNUUN3ME2yMlM2PDdzIN88US=>	M2rQSXNCVkeHUh?=
KU812	NUHISVc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHv1N\|JKSzVyPUKuN\|Y4PzlizszN	M4nRdnNCVkeHUh?=
NY	NWLDUZFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJwM{eyO{DPxE1?	NUHVdYVOW0GQR1XS
HTC-C3	NWHqdHlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTJwNEKyOlch\|ryP	MmLzV2FPT0WU
CFPAC-1	MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfwZ5ZMUUN3ME2yMlQ{QDZ2IN88US=>	MXHTRW5ITVJ?
HH	NIXyUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIm5VItKSzVyPUKuOFk5PTRizszN	MoT3V2FPT0WU
MKN7	NX7GfmJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DNUWlEPTB;Mj62Nlc1QCEQvF2=	NFrSWZRUSU6JRWK=
TE-8	NHLEWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTJwNkO2OVMh\|ryP	MljnV2FPT0WU
MC-IXC	NWX6WZZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTQTWM2OD1{Lk[0OFU{KM7:TR?=	NYrQN3VCW0GQR1XS
DMS-79	NXHvfZE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvOTWM2OD1{Lk[5Nlg1KM7:TR?=	MmX6V2FPT0WU
Detroit562	NGXZ[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTJwNkm4OFUh\|ryP	MUjTRW5ITVJ?
HuP-T4	Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofSTWM2OD1{LkeyPFE5KM7:TR?=	NYLmdYxTW0GQR1XS
QIMR-WIL	NHfxU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTJwN{W5OVIh\|ryP	NUTjOlJ4W0GQR1XS
BB65-RCC	NIP4WGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzaTWM2OD1{LkiwO\|E{KM7:TR?=	MUjTRW5ITVJ?
PC-3	NVfFZ\|V2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDoTWM2OD1{LkizN\|E4KM7:TR?=	Mk\IV2FPT0WU
OVCAR-3	NGHoUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTJwOEW1PVQh\|ryP	MX3TRW5ITVJ?
KYSE-510	NG\sd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHzTWM2OD1{Lki2O\|g3KM7:TR?=	NHPTZVBUSU6JRWK=
HC-1	NFvyeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjCdYdWUUN3ME2yMlk1ODF{IN88US=>	Mn21V2FPT0WU
NCI-H1693	NX7KcZUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1n3NGlEPTB;Mj65OVg6PyEQvF2=	NUjsdmJVW0GQR1XS
DU-4475	M4fxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULJdJpuUUN3ME2yMlk6ODV{IN88US=>	NILFUXpUSU6JRWK=
COLO-680N	NVzTenhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzYSWJKSzVyPUOuNFA1QTVizszN	NFPVbmVUSU6JRWK=
MN-60	NV7pem84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\BeJNZUUN3ME2zMlA1QTd2IN88US=>	NGOzeVRUSU6JRWK=
BCPAP	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTNwMEiyPVUh\|ryP	Mkm5V2FPT0WU
647-V	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTk[2VZUUN3ME2zMlE3OjJizszN	MWrTRW5ITVJ?
HT-1376	M2D4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTNwMkC1NFYh\|ryP	NI[wXHBUSU6JRWK=
NCI-H1793	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLwR5RzUUN3ME2zMlIyODl6IN88US=>	MVrTRW5ITVJ?
SW1463	MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHz4UlZKSzVyPUOuNlYyQTJizszN	NWfKXJRQW0GQR1XS
NCI-H727	MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknUTWM2OD1\|LkO4OVg1KM7:TR?=	NVXn[JlCW0GQR1XS
LB771-HNC	MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVize2I3UUN3ME2zMlM6OTJ4IN88US=>	NYSzPYxsW0GQR1XS
D-542MG	NGj1dlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrLTWM2OD1\|LkS0NlIzKM7:TR?=	NILqZZlUSU6JRWK=
NTERA-S-cl-D1	NHnT[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfuTWM2OD1\|LkS0PVU4KM7:TR?=	M3G2S3NCVkeHUh?=
C8166	M{L4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjVXHc{UUN3ME2zMlQ3PTJzIN88US=>	MmXvV2FPT0WU
639-V	NGS4eXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXDWWdKUUN3ME2zMlU4Pzl{IN88US=>	MYDTRW5ITVJ?
TE-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrTeFZtUUN3ME2zMlU6OTZ7IN88US=>	MkKzV2FPT0WU
OAW-28	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWW2[olxUUN3ME2zMlU6PDJ4IN88US=>	MVPTRW5ITVJ?
SK-LU-1	NVTkWlFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XmO2lEPTB;Mz62NFY1PSEQvF2=	M1TCW3NCVkeHUh?=
CaR-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\ETmFKSzVyPUOuOlExPDhizszN	NFjtRYJUSU6JRWK=
A2780	NYjFNI85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTLNIFKSzVyPUOuOlQxQDlizszN	NWLNcnVCW0GQR1XS
C2BBe1	M1;TZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HWXWlEPTB;Mz62OFQxPyEQvF2=	NIL6b5VUSU6JRWK=
SK-MES-1	NEDrUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PHZWlEPTB;Mz62OFYyPCEQvF2=	M3HqNXNCVkeHUh?=
PANC-10-05	M33Jbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjuTWM2OD1\|LkeyNFczKM7:TR?=	M2LYbXNCVkeHUh?=
J-RT3-T3-5	NHvDd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTNwN{W0NFYh\|ryP	NHnUSZpUSU6JRWK=
ES4	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXmVFRKSzVyPUOuPFIzQDZizszN	MYnTRW5ITVJ?
NCI-H28	Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTZN25KSzVyPUOuPFI6PjFizszN	NIf4[3NUSU6JRWK=
NCI-H1155	NYfGXnh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmS5TWM2OD1\|Lki0NVU6KM7:TR?=	NIn3cGtUSU6JRWK=
KURAMOCHI	MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXvTWM2OD1\|Lki2NFU3KM7:TR?=	NXTiXpA5W0GQR1XS
NCI-H69	M2DaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELDSY1KSzVyPUOuPVAyPzhizszN	MkDEV2FPT0WU
IST-MES1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPFd4ZKSzVyPUOuPVQxOjlizszN	M{mzTHNCVkeHUh?=
NH-12	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELQOotKSzVyPUOuPVQyQDdizszN	MYjTRW5ITVJ?
JVM-2	NVTPdIVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjJS\|FKSzVyPUOuPVQ4PTJizszN	MWHTRW5ITVJ?
EW-16	M1XyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPrTWM2OD1\|Lkm1OVc4KM7:TR?=	NGS5NGFUSU6JRWK=
NCI-H441	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTNwOUewNVQh\|ryP	MYTTRW5ITVJ?
RCC10RGB	MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHmPIZMUUN3ME20MlAyOjR4IN88US=>	NEe5bJhUSU6JRWK=
TCCSUP	Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTRwMUGwOUDPxE1?	M1LweXNCVkeHUh?=
HL-60	NW\iSnNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1n4TGlEPTB;ND6xNlI1OSEQvF2=	NXTEc4NlW0GQR1XS
EW-11	NVvh[nU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTRwMUOyOlEh\|ryP	MYTTRW5ITVJ?
KARPAS-299	NVfLSIRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTRwM{GwNVMh\|ryP	MoDrV2FPT0WU
SNU-C2B	MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\VRoQ5UUN3ME20MlM1Pjh4IN88US=>	NFP1XXdUSU6JRWK=
LU-139	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjKPI1KSzVyPUSuN\|czPDdizszN	M4Li[HNCVkeHUh?=
HCC1937	NEHUO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTRwM{e5PVMh\|ryP	NXjUbmZKW0GQR1XS
GR-ST	NYfC[4NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojHTWM2OD12LkSzNVgh\|ryP	M3u1Z3NCVkeHUh?=
SK-OV-3	M3K1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTRwNE[wOFIh\|ryP	M3jiRnNCVkeHUh?=
A172	MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTRwNUW1NlEh\|ryP	NUHCUFBCW0GQR1XS
NB10	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33iN2lEPTB;ND61PVc5OSEQvF2=	MoLrV2FPT0WU
P30-OHK	NF\Sb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTRwOEG5Nlkh\|ryP	MXjTRW5ITVJ?
KYSE-520	NWTlZWJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHYUnpKSzVyPUSuPFgxOThizszN	NYT1O\|FyW0GQR1XS
KNS-62	M17Pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LuVGlEPTB;ND65NFgxPyEQvF2=	NUnRbndLW0GQR1XS
ES1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnNfJU4UUN3ME20Mlk3ODN3IN88US=>	NIfydItUSU6JRWK=
KOSC-2	Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTRwOUm5OVkh\|ryP	M13VfXNCVkeHUh?=
TE-9	NGXTTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvHdGZKSzVyPUWuNFE2OjVizszN	M{XLRnNCVkeHUh?=
NCI-H1838	M2rjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIqxToZKSzVyPUWuNFIxPzZizszN	MoT2V2FPT0WU
KP-N-YN	Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTVwMUK1PVEh\|ryP	NUDLdIt4W0GQR1XS
ALL-PO	NVLQb5ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTVwMkK1PFch\|ryP	M360d3NCVkeHUh?=
NOMO-1	Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fxRWlEPTB;NT6yN\|E4PiEQvF2=	NH;FcXFUSU6JRWK=
CGTH-W-1	NYOze3dmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\iO3BqUUN3ME21MlM5PTh2IN88US=>	MnSwV2FPT0WU
ATN-1	NF\idlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzvTWM2OD13LkSxNVg1KM7:TR?=	NFnwNopUSU6JRWK=
AGS	NEnnOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTVwNEm2NVgh\|ryP	NUG3bY1bW0GQR1XS
SW13	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\MTWM2OD13LkWzNlY2KM7:TR?=	MX;TRW5ITVJ?
SW1990	M2rGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTVwNkKyPFUh\|ryP	MknpV2FPT0WU
BFTC-905	M2DIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLwTWM2OD13Lk[1PFc5KM7:TR?=	MoDEV2FPT0WU
RMG-I	Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTVwNkW5OFIh\|ryP	NHu1WW9USU6JRWK=
HD-MY-Z	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nZUWlEPTB;NT62PFU5OSEQvF2=	NGD5RVlUSU6JRWK=
HCC1187	MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTVwN{GwN\|Ih\|ryP	NFjDOnVUSU6JRWK=
HCC2998	M33mR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDoXllKSzVyPUWuO\|E5PzdizszN	MUDTRW5ITVJ?
RT-112	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTVwOUCyOFUh\|ryP	NVfae3pxW0GQR1XS
CAKI-1	NI[wRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnOUWpKSzVyPU[uNFA6QDVizszN	MVrTRW5ITVJ?
HDLM-2	NEKzRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVz0UJhGUUN3ME22MlAyPDh7IN88US=>	MmDYV2FPT0WU
TE-10	NILCbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF[zdYJKSzVyPU[uNFQ5OzNizszN	MlHaV2FPT0WU
KE-37	NHX0NIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTZwMEeyOVgh\|ryP	MWnTRW5ITVJ?
RCM-1	M1L0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHiVlZrUUN3ME22MlA4PzF7IN88US=>	MkPZV2FPT0WU
Mewo	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTZwMUG0PFch\|ryP	NX7rNG01W0GQR1XS
L-428	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVH6TXhyUUN3ME22MlE5ODN5IN88US=>	M3TLVXNCVkeHUh?=
8-MG-BA	MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7iW\|NsUUN3ME22MlE6Ozd7IN88US=>	M4H3OHNCVkeHUh?=
SK-MEL-28	MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvRTWM2OD14LkKwPVY4KM7:TR?=	MnnUV2FPT0WU
VA-ES-BJ	M4jHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTZwM{C0OlIh\|ryP	M1i5[3NCVkeHUh?=
CAL-120	NV[yNnBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHT[mtKSzVyPU[uOFUyPjJizszN	NEm3[\|lUSU6JRWK=
GAMG	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfyR41KSzVyPU[uOVA3OiEQvF2=	NHrLPYlUSU6JRWK=
MSTO-221H	M3zzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnsTWM2OD14LkWxNVch\|ryP	M{LY[HNCVkeHUh?=
GCT	NEXH[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWL4cpViUUN3ME22MlU{Ozh5IN88US=>	NF23cJhUSU6JRWK=
SH-4	M4rIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTBTYVHUUN3ME22MlU5QDR2IN88US=>	MojEV2FPT0WU
Calu-3	M3:zUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7WVXZHUUN3ME22MlY2PTZ6IN88US=>	M3fZS3NCVkeHUh?=
SK-HEP-1	NYjjSJNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVSyWpNqUUN3ME22MlcyPzV\|IN88US=>	MnzlV2FPT0WU
PFSK-1	Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFryZ3pKSzVyPU[uO\|M1PzhizszN	M4D1fHNCVkeHUh?=
NB12	NHS3N2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTK[YRKSzVyPU[uO\|g1ODRizszN	NEfVVmJUSU6JRWK=
A388	NVrC[XBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLLTFBKSzVyPU[uPFk2OiEQvF2=	NWrWN251W0GQR1XS
KLE	MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvXTWM2OD14Lkm2OVE3KM7:TR?=	MXLTRW5ITVJ?
TE-11	NXLMW\|JrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\oOYlWUUN3ME23MlA1QTZ5IN88US=>	NWTld21nW0GQR1XS
NCI-H2405	NWTxSoU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rrW2lEPTB;Nz6wPFM6OyEQvF2=	NED4ZpRUSU6JRWK=
OVCAR-4	NGSyOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXTTWM2OD15LkG1N\|Uh\|ryP	NXzldoxJW0GQR1XS
KP-N-YS	MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUSybJJkUUN3ME23MlE5OTRizszN	NIn3W3JUSU6JRWK=
NOS-1	M{PhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTdwMkW4Nlgh\|ryP	MY\TRW5ITVJ?
DMS-114	MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFu2eIRKSzVyPUeuNlk3OzFizszN	NGXtUnpUSU6JRWK=
NCI-H2030	NXHje4JUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTdwM{O2PVgh\|ryP	NGfQPZpUSU6JRWK=
HEL	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jHUGlEPTB;Nz6zO\|UzOSEQvF2=	NVHWbnM4W0GQR1XS
CAL-62	NVyyfVltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\pNGNKSzVyPUeuN\|k5PjZizszN	NY\aSItDW0GQR1XS
COLO-668	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zaVmlEPTB;Nz60N\|k3PyEQvF2=	M3jQ[XNCVkeHUh?=
SKG-IIIa	NYWxdXBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTdwNEWzPFEh\|ryP	MlHGV2FPT0WU
HCC1419	NVfMenZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LHdWlEPTB;Nz60Olg{OyEQvF2=	NVnWTGkyW0GQR1XS
OS-RC-2	NGO2V3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XuUGlEPTB;Nz60PVg6PCEQvF2=	MXjTRW5ITVJ?
COLO-829	M3ni[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTdwNk[0OlMh\|ryP	NEDRNItUSU6JRWK=
NB13	NXrsdZBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjWdGZKSzVyPUeuPFI3PjdizszN	NY\uZVNkW0GQR1XS
DK-MG	Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXxfm9iUUN3ME23Mlg{OjBzIN88US=>	MmLnV2FPT0WU
SHP-77	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XwUWlEPTB;Nz64OlY2OyEQvF2=	NUX6WI1UW0GQR1XS
NCI-H661	NGm3T5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILLT45KSzVyPUiuNFU5PjdizszN	M1iwb3NCVkeHUh?=
AM-38	NHL3XJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRThwMU[yPEDPxE1?	MoDxV2FPT0WU
VM-CUB-1	MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\0OIVKSzVyPUiuNVcxOjlizszN	MWDTRW5ITVJ?
KYSE-70	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDrTo1KSzVyPUiuNVk4PjFizszN	MXfTRW5ITVJ?
5637	MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRThwM{GwOVUh\|ryP	M3O0T3NCVkeHUh?=
TGBC11TKB	M4jxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rlNGlEPTB;OD60OlE3PCEQvF2=	NXrTcXc3W0GQR1XS
EGI-1	NX;FT3hOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLS[ZdKSzVyPUiuOlAxQDhizszN	MnHUV2FPT0WU
D-392MG	NWXmVWVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fLOGlEPTB;OD62OlIyPCEQvF2=	NVuyOId4W0GQR1XS
A673	M3rZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXkbolKSzVyPUiuOlc3OTFizszN	M{XZc3NCVkeHUh?=
COLO-792	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTQOpE{UUN3ME24Mlc1QTR4IN88US=>	MofhV2FPT0WU
NCI-H1792	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPLUphHUUN3ME24Mlg5QTB\|IN88US=>	NVHG[3ZQW0GQR1XS
LS-1034	M{nXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGD1[oZKSzVyPUiuPVQ3PTJizszN	M3jmW3NCVkeHUh?=
D-566MG	Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkj1TWM2OD17LkCxPFEh\|ryP	M2nGfXNCVkeHUh?=
NCI-H226	NFLpZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmL0TWM2OD17LkC5JO69VQ>?	MlvDV2FPT0WU
ChaGo-K-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLwTWM2OD17LkGwOVc6KM7:TR?=	MkXXV2FPT0WU
NCI-H2228	NF[2OVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjSTWM2OD17LkGxNFgyKM7:TR?=	M3f1enNCVkeHUh?=
RPMI-8226	NETzRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvXR4IyUUN3ME25MlEyOzB2IN88US=>	MWnTRW5ITVJ?
BFTC-909	MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PMbGlEPTB;OT6xPFI6PyEQvF2=	M37jNXNCVkeHUh?=
HPAF-II	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHoTWM2OD17LkKyOVE5KM7:TR?=	Mk\EV2FPT0WU
Capan-2	NGfmNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPaOXVKSzVyPUmuOFAyODlizszN	M2DjOnNCVkeHUh?=
IA-LM	NWW0TYVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTlwNEG5OlYh\|ryP	NYj0T3BUW0GQR1XS
KP-4	MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3j2cWlEPTB;OT60PFg{QCEQvF2=	M33ZRXNCVkeHUh?=
A101D	MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHr5dIlKSzVyPUmuOVE4OTlizszN	MkDQV2FPT0WU
EFO-21	M{LFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PrVWlEPTB;OT61PFc{PSEQvF2=	NEjJPJZUSU6JRWK=
C32	MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTmN5lKSzVyPUmuOlM{PCEQvF2=	M3;wfHNCVkeHUh?=
SW837	NWTuXWZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFm5V4tKSzVyPUmuPFQ5OiEQvF2=	NHPZTZVUSU6JRWK=
OCI-AML2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjITWM2OD17Lki2PVYh\|ryP	MlnSV2FPT0WU
NCI-H1355	MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorVTWM2OD17Lkm0NFg5KM7:TR?=	MYLTRW5ITVJ?
NCI-H2342	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDLU5Q6UUN3ME2xNE4xOTV3IN88US=>	NGO3NFVUSU6JRWK=
A204	NH3IUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWC2do1UUUN3ME2xNE4xPDZ4IN88US=>	NHjMZpNUSU6JRWK=
CAL-51	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13YbmlEPTB;MUCuNFg4PyEQvF2=	NEDsVllUSU6JRWK=
HCE-4	NHqzRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULIeGI3UUN3ME2xNE4yOTJ{IN88US=>	Mof2V2FPT0WU
NCI-H810	NV;EOYNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3pTWM2OD1zMD6xOVk4KM7:TR?=	NFfjS2NUSU6JRWK=
DJM-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXDSo13UUN3ME2xNE4yPzN{IN88US=>	MoLPV2FPT0WU
SK-UT-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPXR\|QzUUN3ME2xNE4zPTd2IN88US=>	NXj2b5RXW0GQR1XS
U031	M1vxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\USGlzUUN3ME2xNE4zPjh4IN88US=>	NVrWdJliW0GQR1XS
YH-13	NVjoZVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvP[FFFUUN3ME2xNE4{ODV5IN88US=>	MYTTRW5ITVJ?
K5	Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTKbGlKSzVyPUGwMlM{QTVizszN	MY\TRW5ITVJ?
HEC-1	NEHUUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPmTWM2OD1zMD60NFgyKM7:TR?=	MXTTRW5ITVJ?
A2058	MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vobGlEPTB;MUCuOVQ6OSEQvF2=	NXjUOFhvW0GQR1XS
SW962	NYPuOJpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTFyLk[yNFQh\|ryP	MnjFV2FPT0WU
VMRC-RCZ	NUjaW4pVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnf2TWM2OD1zMD62O\|Q6KM7:TR?=	NETOR4JUSU6JRWK=
D-336MG	M{TvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTFyLkewNFUh\|ryP	NEWwOFZUSU6JRWK=
LXF-289	NEixbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTFyLke5Olch\|ryP	MYnTRW5ITVJ?
SW900	NVPNU5d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTFyLkiyNlgh\|ryP	M3rVS3NCVkeHUh?=
K-562	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTFyLkizPVUh\|ryP	MVzTRW5ITVJ?
HCC38	M2nmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XsbGlEPTB;MUCuPVcyPiEQvF2=	MWjTRW5ITVJ?
SF-295	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTFyLkm5NFIh\|ryP	Mny5V2FPT0WU
LB831-BLC	M1LZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTFzLkK1OVYh\|ryP	NY[2[3ZFW0GQR1XS
FTC-133	NFny[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3yyOGlEPTB;MUGuN\|A5OSEQvF2=	NW[2NFIyW0GQR1XS
HCC1954	NYryRZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTFzLkSzOkDPxE1?	MVPTRW5ITVJ?
GOTO	NYO4Umg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXhTWM2OD1zMT61NlA3KM7:TR?=	NIL1N3VUSU6JRWK=
LS-411N	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTFzLk[xNFEh\|ryP	MkTDV2FPT0WU
RPMI-7951	MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLOUYZKSzVyPUGxMlY{PDhizszN	NGrs[4hUSU6JRWK=
NCI-H1299	M2XZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTXTXdzUUN3ME2xNU43PjR5IN88US=>	NHz2V49USU6JRWK=
MLMA	MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXmb5RwUUN3ME2xNU43QTl5IN88US=>	M2rqbHNCVkeHUh?=
MMAC-SF	NELTWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rpb2lEPTB;MUGuO\|I2OiEQvF2=	NW\y[GVzW0GQR1XS
UM-UC-3	NICyZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjiTWM2OD1zMT63OFIyKM7:TR?=	NX3RRWpYW0GQR1XS
SCC-9	M4\GWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;TfVNKSzVyPUGxMlgyPTFizszN	MlHxV2FPT0WU
HOS	M2\4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfvTWM2OD1zMT64Olg{KM7:TR?=	NXrZN4VwW0GQR1XS
OE19	M2jqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTFzLkmzOlch\|ryP	Mk\2V2FPT0WU
Mo-T	MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfNXmp1UUN3ME2xNU46PTRzIN88US=>	MkXCV2FPT0WU
CAMA-1	MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIP0dYpKSzVyPUGyMlE3OzNizszN	NFraT3lUSU6JRWK=
U-118-MG	M3PWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fTPWlEPTB;MUKuNlQ1OSEQvF2=	NIXZeVBUSU6JRWK=
KS-1	NYrWe49lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nF[GlEPTB;MUKuNlg{OiEQvF2=	Mkm5V2FPT0WU
JAR	NWfDW2diT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;ERWlEPTB;MUKuN\|M3QSEQvF2=	NVr4UJE{W0GQR1XS
ABC-1	NIfPR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTTTWM2OD1zMj6zOFEh\|ryP	MWPTRW5ITVJ?
Daoy	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULnOXR1UUN3ME2xNk41PTR{IN88US=>	MWfTRW5ITVJ?
C3A	NGDDWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfOTWM2OD1zMj61O\|g2KM7:TR?=	NUnscHpiW0GQR1XS
GT3TKB	MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXuxTVNlUUN3ME2xNk43OzJ5IN88US=>	Mm\pV2FPT0WU
DMS-273	NIL4N\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DiSmlEPTB;MUKuPFY{OyEQvF2=	M3H4PXNCVkeHUh?=
G-361	M4ThPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUD1OJRXUUN3ME2xNk46OTJ7IN88US=>	M3fz[3NCVkeHUh?=
RH-18	M3Hle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTF\|LkK5OlIh\|ryP	Moj0V2FPT0WU
SN12C	M2fSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzGWYVKSzVyPUGzMlM5ODhizszN	NEHCNHFUSU6JRWK=
NCI-H1993	NV\aR5VyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\1[2lEPTB;MUOuOFI5PSEQvF2=	NH3jdJdUSU6JRWK=
LOXIMVI	M{XPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TzVWlEPTB;MUOuOlE2OSEQvF2=	NYLYcmFVW0GQR1XS
SK-PN-DW	Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLuTWM2OD1zMz64OFI4KM7:TR?=	NHTTZVZUSU6JRWK=
KALS-1	NF72W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfLTVFxUUN3ME2xN{45PTJ3IN88US=>	NYHwbm9CW0GQR1XS
LAN-6	NGfDSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTF2LkK1N{DPxE1?	MknwV2FPT0WU
A549	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HyNmlEPTB;MUSuOFcyOiEQvF2=	MV\TRW5ITVJ?
RD	Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTF2LkS4NVMh\|ryP	NU[x[ZY5W0GQR1XS
TGBC1TKB	Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTF2Lk[2NVUh\|ryP	MYDTRW5ITVJ?
NCI-H630	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTF2Lkm0Olch\|ryP	M3\VOHNCVkeHUh?=
MIA-PaCa-2	NYO4ZVRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWi5Sm9sUUN3ME2xOE46PjlizszN	NFzWPJJUSU6JRWK=
NCI-H1755	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkG4TWM2OD1zND65PVU{KM7:TR?=	MVLTRW5ITVJ?
MOLT-4	NVLhUmNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDNTWM2OD1zNT6wOFk4KM7:TR?=	M4XPenNCVkeHUh?=
CW-2	NILNUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTF3LkG0NlEh\|ryP	M4HZdHNCVkeHUh?=
COLO-320-HSR	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPJ[pdiUUN3ME2xOU42OzB5IN88US=>	M1;WPXNCVkeHUh?=
UMC-11	NHiyTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2D2dGlEPTB;MUWuO\|UzOyEQvF2=	Mn\rV2FPT0WU
MCF7	NVTjRndbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\JTWM2OD1zNT64NVQ2KM7:TR?=	MXjTRW5ITVJ?
NCI-H23	M3KzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnUcJVKSzVyPUG1Mlg1OzhizszN	MUfTRW5ITVJ?
HuCCT1	M2LQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M133RmlEPTB;MUWuPFc1KM7:TR?=	NF3Db\|BUSU6JRWK=
MPP-89	NVj0[292T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXeyO4RoUUN3ME2xOU46PDF5IN88US=>	NGrYbGRUSU6JRWK=
HT55	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\3TmVKSzVyPUG1Mlk1PzhizszN	NIXWT4ZUSU6JRWK=
no-11	MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rQOGlEPTB;MUWuPVY3OyEQvF2=	NWXjXlYxW0GQR1XS
GP5d	M1zzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DFeWlEPTB;MU[uNlE5PyEQvF2=	NVP1NFZOW0GQR1XS
BHT-101	NXryRZNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrZPIVKSzVyPUG2MlI1OzlizszN	MnHIV2FPT0WU
M059J	M3H5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjKT4RKSzVyPUG2MlI5PCEQvF2=	M33CfnNCVkeHUh?=
D-283MED	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIG2[YJKSzVyPUG2MlQzODlizszN	MnHpV2FPT0WU
BEN	MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;KSHV[UUN3ME2xOk42OTV3IN88US=>	NWe0b41KW0GQR1XS
LB373-MEL-D	Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWniRVNNUUN3ME2xOk44OjN{IN88US=>	NFW5bYNUSU6JRWK=
MEL-HO	NUXPU3lkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFy0ZpJKSzVyPUG2Mlg5PTRizszN	NYnHRXFNW0GQR1XS
GI-ME-N	M1nnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTF4LkmwN\|Ih\|ryP	M1zwSHNCVkeHUh?=
RKO	NUHmRVRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTF5LkC3OFgh\|ryP	NVTCeI9DW0GQR1XS
MZ2-MEL	MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlftTWM2OD1zNz6xN\|Mh\|ryP	NX\IbY5IW0GQR1XS
NCI-H1573	M2Hs[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULyT45IUUN3ME2xO{4zQDJ4IN88US=>	M{THXXNCVkeHUh?=
NCI-H1581	Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jqfWlEPTB;MUeuOFQyOSEQvF2=	NX;lWIgzW0GQR1XS
NCI-H747	M3SwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fxb2lEPTB;MUeuOVI6PyEQvF2=	MYjTRW5ITVJ?
SW1783	NHTodZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFP5[FdKSzVyPUG3MlY1OTVizszN	MkHWV2FPT0WU
Calu-6	M1PuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfrU\|l3UUN3ME2xO{43Pzh{IN88US=>	MYTTRW5ITVJ?
SF268	NUPlelV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfIfGtOUUN3ME2xO{43QTZ7IN88US=>	NFvL[oxUSU6JRWK=
ES8	NHHBOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXlVHBKSzVyPUG3Mlg2QTNizszN	NX7zXnJTW0GQR1XS
KM-H2	NEHV[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTF5Lkm0NVEh\|ryP	NVPLV\|RoW0GQR1XS
D-502MG	MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3KTWM2OD1zNz65PFA5KM7:TR?=	M4DGSXNCVkeHUh?=
HLE	Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXizNJdDUUN3ME2xPE4{OTR6IN88US=>	MkS1V2FPT0WU
SW982	MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jaNmlEPTB;MUiuOFA4PSEQvF2=	MkfuV2FPT0WU
MDA-MB-361	Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTF6LkW1PFgh\|ryP	MnOwV2FPT0WU
NCI-H1563	NUP2R5hkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHDVlc1UUN3ME2xPE44OTJ2IN88US=>	M1[wb3NCVkeHUh?=
MFE-280	Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTF6LkeyPVMh\|ryP	Ml3BV2FPT0WU
U251	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{H6cmlEPTB;MUiuO\|M1PyEQvF2=	MUXTRW5ITVJ?
KNS-42	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrwTWM2OD1zOD64NFE2KM7:TR?=	M2HvcXNCVkeHUh?=
U-266	NYHxbZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXVNIlKSzVyPUG4Mlg3PDlizszN	MXfTRW5ITVJ?
OVCAR-8	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTF6LkmyO\|Yh\|ryP	MYjTRW5ITVJ?
MFH-ino	MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHHbXBKSzVyPUG4Mlk3PjlizszN	MluwV2FPT0WU
D-263MG	NUjGXIs3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVj4c3JtUUN3ME2xPU4xOTd{IN88US=>	NFfCSHRUSU6JRWK=
NCI-H1437	Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWP4XnZGUUN3ME2xPU4xPDZ5IN88US=>	NVXzR4FKW0GQR1XS
NCI-H1048	MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTF7LkKzNlYh\|ryP	M{HMXHNCVkeHUh?=
NCI-H446	NV;tSm9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTF7LkO1PFkh\|ryP	MonXV2FPT0WU
NCI-N87	NEP3bYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTGTWM2OD1zOT61PVkzKM7:TR?=	NG\id2JUSU6JRWK=
WM-115	NVXkUpBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnQdFBKSzVyPUG5MlY4PzRizszN	MUHTRW5ITVJ?
HuH-7	NGnzdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmi0TWM2OD1zOT63OFIyKM7:TR?=	MUjTRW5ITVJ?
NCI-H650	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWG4[YVtUUN3ME2xPU44PTB6IN88US=>	NILab29USU6JRWK=
TYK-nu	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTF7LkizO\|gh\|ryP	M{\2XXNCVkeHUh?=
Becker	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTF7Lki1OFch\|ryP	NYHrU4RHW0GQR1XS
BB49-HNC	M4rUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzCW2VyUUN3ME2xPU46OiEQvF2=	NI\xeFRUSU6JRWK=
HGC-27	NHTPfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPPcGlKSzVyPUKwMlE{QTRizszN	MXrTRW5ITVJ?
SiHa	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTJyLkO3NVIh\|ryP	NHWyfoNUSU6JRWK=
LB2518-MEL	Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\5XWlEPTB;MkCuN\|c{QSEQvF2=	M4mxZXNCVkeHUh?=
TE-5	M1nuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlroTWM2OD1{MD63OFgzKM7:TR?=	NYnEdVlHW0GQR1XS
IST-SL1	NGnCW\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHnTWM2OD1{MD63PFc6KM7:TR?=	NY[zOGtOW0GQR1XS
A375	NEXvWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlqzTWM2OD1{MT6wOVY4KM7:TR?=	MYDTRW5ITVJ?
MC116	NY\wWWhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWD0R4M{UUN3ME2yNU4xPzJ\|IN88US=>	M2[3TnNCVkeHUh?=
GI-1	MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTJzLkG3JO69VQ>?	MmS2V2FPT0WU
HOP-62	NYjNNJlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzjTWM2OD1{MT6yO\|g1KM7:TR?=	NIf6[2FUSU6JRWK=
PA-1	MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7oTJdKSzVyPUKxMlI4QDdizszN	M3vXN3NCVkeHUh?=
HT	MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTJzLkSzN\|Eh\|ryP	M{\GUnNCVkeHUh?=
HUTU-80	NH\5dpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjaN4dlUUN3ME2yNU41OzN4IN88US=>	MlTzV2FPT0WU
NCI-H1975	MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfsTWM2OD1{MT60OlEh\|ryP	MoD5V2FPT0WU
GAK	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{ixU2lEPTB;MkGuOFk6KM7:TR?=	NHzmSHZUSU6JRWK=
SK-N-AS	NWr2VGxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPxTWlOUUN3ME2yNU42PjF7IN88US=>	M335XXNCVkeHUh?=
OE33	M1HPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTJzLk[wOFYh\|ryP	M2TJfXNCVkeHUh?=
YKG-1	M37FUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzFTWM2OD1{MT62OVQ2KM7:TR?=	MYHTRW5ITVJ?
CAL-85	NHvzWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDIWmpKSzVyPUKxMlk{ODVizszN	MVPTRW5ITVJ?
NCI-H2347	M2jTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3ewUGlEPTB;MkGuPVQzQCEQvF2=	MYXTRW5ITVJ?
PANC-08-13	NWXTfYxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIG5WmdKSzVyPUKyMlAyOTlizszN	Mn;UV2FPT0WU
SK-N-FI	NF3ZRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\vcZJKSzVyPUKyMlMxPzRizszN	NXKwSY9qW0GQR1XS
NEC8	NWrXZ\|l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIGydIVKSzVyPUKyMlUxPzhizszN	NH3sbHdUSU6JRWK=
AN3-CA	MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1e1O2lEPTB;MkKuOlA5PCEQvF2=	MnnpV2FPT0WU
HuO9	NHy3Um9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTJ{LkezPVYh\|ryP	NXLRbVBOW0GQR1XS
COLO-800	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTJ{Lke2OVMh\|ryP	NXq3bIxxW0GQR1XS
HT-29	NGLPfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{GxbmlEPTB;MkKuPFgzOyEQvF2=	NYroSYRwW0GQR1XS
OC-314	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTJ{Lki4OFUh\|ryP	NF7MVYxUSU6JRWK=
G-401	NEXYS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzzNopKSzVyPUKzMlA1PjJizszN	NWm3dIFZW0GQR1XS
Saos-2	NXHw[otUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHObVdKSzVyPUKzMlUyQDJizszN	MW\TRW5ITVJ?
UACC-62	NF2yU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTJ\|LkW4N\|Mh\|ryP	NUDKdnBYW0GQR1XS
D-247MG	MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{ntOWlEPTB;MkOuO\|k{QSEQvF2=	MnTzV2FPT0WU
COLO-741	NXXiR\|JKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjEfWJKSzVyPUKzMlk2PjVizszN	NVvLRVhNW0GQR1XS
ES3	NGXWSmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml[yTWM2OD1{ND6wNFI{KM7:TR?=	MUXTRW5ITVJ?
LNCaP-Clone-FGC	M2nzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTJ2LkCyNVEh\|ryP	MkDZV2FPT0WU
SW1710	NVzM[\|lTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTJ2LkG1NFYh\|ryP	NX;pRXVxW0GQR1XS
LU-99A	Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPhS3VKSzVyPUK0MlE5PDFizszN	M4nySnNCVkeHUh?=
HOP-92	NXPScYFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{O2NWlEPTB;MkSuO\|I2KM7:TR?=	M2DNeHNCVkeHUh?=
LS-123	NIjadINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnhTWM2OD1{ND65OlE1KM7:TR?=	Mn;tV2FPT0WU
T84	M{nESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVf1R3NZUUN3ME2yOE46PzZ3IN88US=>	NF24WppUSU6JRWK=
HCT-116	NHPJUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkK3TWM2OD1{NT60NVg3KM7:TR?=	MX7TRW5ITVJ?
M14	NHrEWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTJ3LkS0OFch\|ryP	NULjb\|NRW0GQR1XS
OCUB-M	NFfVUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHXTWM2OD1{NT60OFU3KM7:TR?=	NH6wZnBUSU6JRWK=
MKN45	NEHYTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYmx[pRMUUN3ME2yOU43OzF3IN88US=>	M4TtT3NCVkeHUh?=
LCLC-97TM1	MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX35fHY2UUN3ME2yOU44Ojh3IN88US=>	NEPWPVBUSU6JRWK=
RVH-421	M2G2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIW2VXVKSzVyPUK1MlgyPjFizszN	M2PyWnNCVkeHUh?=
NKS-81-FD	M4PC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jLT2lEPTB;MkWuPVAzOSEQvF2=	Mk\HV2FPT0WU
NCI-H596	NU[2XGF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEW4fHJKSzVyPUK2MlA1QDdizszN	NXzpO2ZMW0GQR1XS
GB-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWewbFFQUUN3ME2yOk4yQDd7IN88US=>	M2nnXnNCVkeHUh?=
ZR-75-30	NGLNUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;OcoNKSzVyPUK2MlIzQTdizszN	NFXVRmpUSU6JRWK=
U-2-OS	M1XtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUj6R2lNUUN3ME2yOk4{PzV5IN88US=>	NW\mZWNwW0GQR1XS
HuP-T3	MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fFTWlEPTB;Mk[uOlExOiEQvF2=	Mkf3V2FPT0WU
MOLT-16	NXTuT41wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmS3TWM2OD1{Nj62NVY3KM7:TR?=	NGXIVZBUSU6JRWK=
U-87-MG	NE\tcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTJ4Lke0N\|gh\|ryP	MnLpV2FPT0WU
8505C	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvPU3l{UUN3ME2yOk46OTJ4IN88US=>	MU\TRW5ITVJ?
SK-MEL-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrBTWM2OD1{Nj65PFI5KM7:TR?=	MXjTRW5ITVJ?
COLO-824	NHfl[\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTJ5LkKxPVUh\|ryP	MlPPV2FPT0WU
EW-1	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlu5TWM2OD1{Nz6zOVU1KM7:TR?=	MXLTRW5ITVJ?
UACC-257	NInYc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjpTWM2OD1{Nz6zPFA1KM7:TR?=	Mm\4V2FPT0WU
Hs-578-T	NYe1bpljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXERoUyUUN3ME2yO{42Ojl7IN88US=>	NXPpdW9DW0GQR1XS
UACC-893	NEC4SJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrZboppUUN3ME2yO{43PjNzIN88US=>	MWnTRW5ITVJ?
MHH-NB-11	M3fFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nJd2lEPTB;MkeuPFAxPyEQvF2=	MlX5V2FPT0WU
KYSE-410	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2[2UmlEPTB;MkiuNlc4QSEQvF2=	MU\TRW5ITVJ?
SF126	NXj0PGRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3PbFlKSzVyPUK4Mlc1OzVizszN	Mo[1V2FPT0WU
HT-144	NVfvR\|RIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rqOmlEPTB;MkmuN\|M3OiEQvF2=	MonNV2FPT0WU
SW1573	NEjWVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHSWHZKSzVyPUK5MlM2ODlizszN	NEe3VYhUSU6JRWK=
SW620	M4ixV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXLVG5KSzVyPUK5MlM3PDFizszN	M3G2VnNCVkeHUh?=
SCH	NGTBeJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTJ7Lki4N\|Eh\|ryP	Mkf4V2FPT0WU
EW-22	MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrRRmhKSzVyPUOwMlE6PjlizszN	Mlv6V2FPT0WU
H4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLjNIhKSzVyPUOwMlQ3PTRizszN	MUfTRW5ITVJ?
CAS-1	NW\h[lJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\GTWM2OD1\|MD63PFU6KM7:TR?=	MlqyV2FPT0WU
MG-63	NHrvRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLqTWM2OD1\|MD64OFc5KM7:TR?=	Mk[3V2FPT0WU
MDA-MB-415	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTNzLkG3OVMh\|ryP	MVTTRW5ITVJ?
NCI-H1395	Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnEOnVKSzVyPUOxMlI{OjhizszN	MmjPV2FPT0WU
Ca-Ski	NUHmdodjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXi1OG8zUUN3ME2zNU4{OTd5IN88US=>	M1LudnNCVkeHUh?=
BxPC-3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTNzLkO3Nlkh\|ryP	M1rMXnNCVkeHUh?=
A3-KAW	M1nkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTNzLkS0O\|Eh\|ryP	MYrTRW5ITVJ?
T-24	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF6zT2pKSzVyPUOxMlc{PjJizszN	NE\LcY1USU6JRWK=
NCI-H2029	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPqb3lKSzVyPUOxMlc4PjVizszN	Mof2V2FPT0WU
YAPC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PP[GlEPTB;M{KuNFQxPyEQvF2=	Mk\sV2FPT0WU
SK-MEL-2	NYDJenZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4H2[2lEPTB;M{KuNFUzKM7:TR?=	MUTTRW5ITVJ?
LS-513	NUnzdYRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfSRXBxUUN3ME2zNk4yOTh5IN88US=>	M2nNfnNCVkeHUh?=
AsPC-1	M2nFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXv4fVRvUUN3ME2zNk4{PjB3IN88US=>	NFzjd4FUSU6JRWK=
KYSE-150	NVvxNpllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWn2VWhXUUN3ME2zNk4{Pzd\|IN88US=>	NX7hNnpqW0GQR1XS
NCI-H520	M{f6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETweIFKSzVyPUOyMlQ1QDJizszN	NETHR2lUSU6JRWK=
JEG-3	M1;LXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3z4Z2lEPTB;M{OuNFk4OSEQvF2=	NHjhXJpUSU6JRWK=
GMS-10	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\TTWM2OD1\|Mz6zNFA1KM7:TR?=	M1;LU3NCVkeHUh?=
HT-1080	M4rpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTN\|LkO5JO69VQ>?	M4q3THNCVkeHUh?=
NCI-H1651	Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTN\|LkO5OkDPxE1?	NWjXOG9FW0GQR1XS
NCI-H2122	MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1juVWlEPTB;M{OuOVU4PCEQvF2=	NHXtNo1USU6JRWK=
ES5	NXyzPXVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlizTWM2OD1\|Mz63NlkzKM7:TR?=	M{nBenNCVkeHUh?=
8305C	MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTN\|Lkm5N\|ch\|ryP	MVvTRW5ITVJ?
KM12	M17id2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vVZWlEPTB;M{SuNFQ4QCEQvF2=	NV;MWWRHW0GQR1XS
HCT-15	NFXqfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnITWM2OD1\|ND6xNlch\|ryP	NXrmO3d7W0GQR1XS
OVCAR-5	M4fvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTN2LkKxPFIh\|ryP	M1v2RnNCVkeHUh?=
NCI-H2291	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH[0UJBKSzVyPUO0MlI1PzJizszN	MU\TRW5ITVJ?
CP50-MEL-B	MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTN2Lk[1PVIh\|ryP	MYTTRW5ITVJ?
C-33-A	NHTkVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHPfWRiUUN3ME2zOE43QDV5IN88US=>	NUDsSGFFW0GQR1XS
NCI-H2452	MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zFNmlEPTB;M{SuO\|g5OiEQvF2=	Mk\OV2FPT0WU
MDA-MB-157	MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzoR5dKSzVyPUO0MlgyQTNizszN	NXTQT3RGW0GQR1XS
LN-405	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTN3LkSzNFgh\|ryP	M{ThTHNCVkeHUh?=
MDA-MB-231	NHL3XWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTN3LkWwOVQh\|ryP	NWnDU\|hSW0GQR1XS
EW-24	NWT1T4dIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHMSok2UUN3ME2zOU43OzN3IN88US=>	Mn3rV2FPT0WU
MKN28	M3vCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DhVGlEPTB;M{WuPFI{PiEQvF2=	NHHJW3ZUSU6JRWK=
KINGS-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTN3Lki0N\|Qh\|ryP	M{jvVnNCVkeHUh?=
LC-2-ad	NVXCcZozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rYe2lEPTB;M{[uOlk6KM7:TR?=	NXG0UlB3W0GQR1XS
IGR-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHQV4c6UUN3ME2zOk44ODd3IN88US=>	MWjTRW5ITVJ?
SW626	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHu[\|RKSzVyPUO3MlA1OTdizszN	NWXYbG0zW0GQR1XS
ONS-76	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PEN2lEPTB;M{euNVMxQSEQvF2=	NWXwSGtTW0GQR1XS
T98G	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;jWG1RUUN3ME2zO{45PjN3IN88US=>	MV;TRW5ITVJ?
NB14	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPsTWM2OD1\|OD60OVQ1KM7:TR?=	MW\TRW5ITVJ?
D-423MG	MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vNZ2lEPTB;M{iuOFg3QSEQvF2=	M2K5N3NCVkeHUh?=
NCI-H510A	M3PZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXQUGxKSzVyPUO4MlY1PTFizszN	M{Ti[nNCVkeHUh?=
NMC-G1	NGDCNW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGToboFKSzVyPUO4MlczOjJizszN	MlK2V2FPT0WU
SW948	M325Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrpeWFKSzVyPUO4Mlg6PDlizszN	M3TKTnNCVkeHUh?=
MFM-223	NFvJZ\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnBeZdKSzVyPUO4Mlk1OzFizszN	NWHxTpZSW0GQR1XS
PAN1	NUXzRY9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjsTWM2OD1\|OD65PVE6KM7:TR?=	NGrkbWJUSU6JRWK=
MZ7-mel	MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHMdpk{UUN3ME2zPU4yOTl7IN88US=>	NF7TUVRUSU6JRWK=
COLO-679	NHLVToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\rbGlEPTB;M{muPVcxQCEQvF2=	NF[5doNUSU6JRWK=
SW872	NHXvdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfCZXR5UUN3ME20NE4zODNzIN88US=>	NYnVb3p1W0GQR1XS
HT-1197	MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTRyLkK4Olkh\|ryP	M{LDWnNCVkeHUh?=
ES6	MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYr1TnIxUUN3ME20NE41PTV{IN88US=>	MlzZV2FPT0WU
SNU-387	NWC0W2tUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPSTWM2OD12MD64NlM5KM7:TR?=	MUHTRW5ITVJ?
T47D	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DnemlEPTB;NEGuNFE6OiEQvF2=	MV;TRW5ITVJ?
G-402	M3z3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTRzLkC4NFkh\|ryP	MUnTRW5ITVJ?
MZ1-PC	NHvnNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELuNoNKSzVyPUSxMlgyKM7:TR?=	NYPyTZNiW0GQR1XS
SW1417	NITEcVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjsZmNKSzVyPUSyMlMxOyEQvF2=	MULTRW5ITVJ?
RERF-LC-MS	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTR{LkWwPFch\|ryP	MYLTRW5ITVJ?
SF539	NGPp[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTR{LkW1Nlkh\|ryP	NXLhOXNPW0GQR1XS
ESS-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTR\|LkW1OVgh\|ryP	NGnycVVUSU6JRWK=
RO82-W-1	NFHSfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml2yTWM2OD12Mz62NVU{KM7:TR?=	NUfIUWxJW0GQR1XS
S-117	Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoL6TWM2OD12Mz62PVU5KM7:TR?=	MlrTV2FPT0WU
SW756	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTR\|LkiyOFIh\|ryP	MlHYV2FPT0WU
CP66-MEL	M4HZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3p[oJMUUN3ME20OU44OTR\|IN88US=>	NEDlXGpUSU6JRWK=
H-EMC-SS	M17FZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnHTWM2OD12NT63Olk{KM7:TR?=	MWLTRW5ITVJ?
NCI-H2052	M{Szc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfKbIRKSzVyPUS1MlkxOjdizszN	M{\NfXNCVkeHUh?=
SW684	NUHCfmZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTR5LkCwPFEh\|ryP	MVrTRW5ITVJ?
HCC1569	M1nnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTR5LkG2OVgh\|ryP	M1GweXNCVkeHUh?=
KGN	M4\FT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1O0[GlEPTB;NEeuN\|MyOSEQvF2=	MWPTRW5ITVJ?
LCLC-103H	M{LMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LaNmlEPTB;NEeuOFQxPCEQvF2=	MVzTRW5ITVJ?
SW780	NHfxNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrrUHltUUN3ME20O{43OzVzIN88US=>	M{XNVHNCVkeHUh?=
NCI-H1703	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVP5cJVzUUN3ME20PE4{OzV{IN88US=>	MkjxV2FPT0WU
HCC1395	MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETZdnFKSzVyPUS4Mlc1OzJizszN	NXnUdJhUW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo

Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. ^[3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. ^[4]

Protocol

Cell Research:^[1]	+ Expand Cell lines: NR6, NR6M and NR6W cells Concentrations: 0-2 μM Incubation Time: 72 hours Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay. (Only for Reference)
Animal Research:^[3]	+ Expand Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells. Formulation: 0.5% polysorbate Dosages: 100 mg/kg Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days (Only for Reference)

Cell Research:^[1]

+ Expand

Cell lines: NR6, NR6M and NR6W cells
Concentrations: 0-2 μM
Incubation Time: 72 hours
Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.
(Only for Reference)

Animal Research:^[3]

+ Expand

Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Formulation: 0.5% polysorbate
Dosages: 100 mg/kg
Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days
(Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gefitinib (ZD1839) SDF

Molecular Weight	446.90
Formula	C₂₂H₂₄ClFN₄O₃
CAS No.	184475-35-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03866499	Not yet recruiting	NSCLC	Beta Pharma Inc.	May 2019	Phase 3
NCT03866499	Not yet recruiting	NSCLC	Beta Pharma Inc.	May 2019	Phase 3
NCT03787992	Not yet recruiting	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	Allist Pharmaceuticals Inc.	April 1 2019	Phase 3
NCT03787992	Not yet recruiting	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	Allist Pharmaceuticals Inc.	April 1 2019	Phase 3
NCT03766490	Not yet recruiting	Non-Small-Cell Lung	The First Affiliated Hospital of Soochow University\|The First People''s Hospital of Changzhou\|Second Affiliated Hospital of Soochow University\|Nantong University\|Affiliated Hospital of Jiangnan University\|Jiangyin People''s Hospital\|Changzhou No.2 People''s Hospital\|Chia Tai Tianqing Pharmaceutical Group Co. Ltd.	March 30 2019	Not Applicable
NCT03856697	Not yet recruiting	Advanced Non-small Cell Lung Cancer	Hangzhou ACEA Pharmaceutical Research Co. Ltd.\|Guangdong Provincial People''s Hospital	March 2019	Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
Answer:
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products4

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686, AVL-301)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)

Cited by 95 Publications

14 Customer Reviews

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Gefitinib (ZD1839) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)

Cited by 95 Publications

14 Customer Reviews

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Gefitinib (ZD1839) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)